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1 Zusammenfassung/ Abstract 
 
1.1 Zusammenfassung 
 
Die hämtopoetische Stammzelltransplantation (HSZT) ist eine vielversprechende, kurative 
Behandlungsmöglichkeit für eine Vielzahl von Krankheiten, wie zum Beispiel Leukämien, 
malignen Lymphknotenerkrankungen und angeborenen Immundefekten. Das Ziel der HSZT 
liegt in der Wiederherstellung einer durch Spenderzellen vermittelnden Hämatopoese im 
Patienten (Transplantationsempfänger). Dieser Prozess, auch als Chimärismus bezeichnet, 
soll langfristig den zumindest teilweisen Ersatz des eigenen Immunsystems durch das des 
Spenders gewährleisten. Damit die transplantierten Stammzellen anwachsen können ohne 
abgestoßen zu werden, muss sich der Patient zuvor einer immunsuppressiven Behandlung 
mittels Radio- und/ oder Chemotherapie unterziehen. Jedoch ist die HSZT für den Patienten 
mit erheblichen Risiken verbunden und ihre Anwendung daher derzeit auf vital bedrohliche 
Erkrankungen limitiert, da es infolgedessen zu bedrohlichen Infektionskrankheiten und/ oder 
einer Allo-Immunreaktion („graft-versus-host“ – GvHD) kommen kann. Tatsächlich ist die 
GvHD, bei der die transplantierten allo-reaktiven T Lymphozyten des Spenders die Organe 
des Patienten als fremd erkennen und bekämpfen, eine häufig auftretende, ungewollte und 
gefürchtete Nebenerscheinung. Daher führt die Kombination aus Immunsuppression, 
verzögerter Wiederherstellung des Immunsystems durch neugebildete Immunzellen, 
Infektionen und GvHD zu einer hohen Morbiditäts- und Mortalitätsrate bei HSZT 
Empfängern. Abhilfe dafür kann eine T Zellpopulation leisten, die trotz Ausschaltung/ 
Reduktion ihres allo-reaktiven Potentials ihre Effektivität gegen pathogene Infektionserreger 
und maligne Empfängerzellen beibehält. Eine Möglichkeit besteht in der Anwendung des 
pharmakologisch hergestellten Fusionsproteins CTLA4-Ig. In vitro Studien haben gezeigt, 
dass CTLA4-Ig die antigen-spezifische Immunantwort unterdrückt (Anergie), indem es die 
CD28:CD80/86 Co-Stimulation blockiert. Weiters wurde postuliert, dass dessen Wirkung zur 
Ausbildung eines spezifischen regulatorischen Phänotyps Dendritischer Zellen (DZ), 
vermittelt durch die Aktivität des Tryptophan – metabolisierenden Enzyms Indolamin-2,3-
Dioxygenase (IDO), führt. Auf Basis dieser Erkenntnisse wurde in der vorliegenden Studie 
die immuno-regulatorisch vermittelnde Rolle von CTLA4-Ig in einem allogenen in vitro 
Modell basierend auf Mauszellen untersucht, in dem allogene Balb/c T Zellen mit C57BL/6 
DZ, generiert aus Milz und Knochenmark, co-kultiviert wurden. Es konnte gezeigt werden, 
dass die Präsenz von CTLA-4Ig während der Co-Kultur zu einer starken Unterdrückung der 
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allogenen T-Zell Antwort führte. Dieser inhibierende Effekt durch CTLA-4Ig konnte jedoch 
weder mit der Aktivierung des immuno-modulatorischen Enzyms IDO, noch mit der 
Induktion eines DZ regulatorischen Phänotyps in Verbindung gebracht werden sondern 
beeinträchtigte direkt die Interaktion von T-Lymphozyten und DZ in der Co-Kultur und betraf 
präferenziell die CD4+ T- Zell Antwort. Weiters konnte in diesen CD4+ T-Zell Populationen 
eine hohe CD25+CD62L+FoxP3+ Expression, kompatibel mit einem regulatorischen 
Phänotyp, nachgewiesen werden. Dieser regulatorische Phänotyp konnte sogar nach 
Restimulation aufrechterhalten werden. 
Zusammenfassend, CTLA-4Ig hemmt die allogene proliferierende T Zell Antwort auf eine 
IDO unabhängige Art und Weise und fördert die Ausbildung eines regulatorischen T Zell 
Phänotyps. Die Expansion regulatorischer T Zellen, vermittelt durch CTLA-4Ig, stellt 
möglicherweise eine neue therapeutische Alternative dar um Nebenwirkungen, die während 
einer Stammzelltransplantation auftreten, zu lindern. 
 
1.2 Abstract 
 
Hematopoietic stem cell transplantation (HSCT) has emerged as a promising curative 
treatment modality for a variety of diseases, including leukemia, lymphoma and congenital 
immunodeficiency syndromes. The ambition of a successful HSCT is to stably establish and 
maintain donor-type hematopoiesis in the recipient, termed chimerism. Successful 
introduction of a stable chimerism implies a profound and prolonged manipulation of the 
recipient immune system which is achieved by radiation and/ or chemotherapy. This 
immunosuppressive conditioning is necessary to mediate engraftment and to prevent 
rejection. Furthermore, it eradicates additional residual malignant diseases. Thus, during a 
prolonged period of immune suppression and dysregulation after HSCT, the patient is at high 
risk for developing severe infections or graft-versus-host disease (GvHD) since immune 
reconstitution is slow and functionally impaired. Due to the high frequency of allo-reactive T 
cells, the risk of GvHD is much higher than the capability to develop protective immunity 
against environmental pathogens during T cell reconstitution. All these facts contribute to a 
major extent to transplant related morbidity and mortality (TRM). 
T cells specifically tolerant against recipient allo-antigens are critical to provide recipients of 
HSCT with T cell immunity without promoting GvHD. The chimeric protein CTLA-4Ig was 
previously described to induce antigen-specific T cell unresponsiveness (anergy) in vitro by 
blocking the CD28:CD80/86 costimulatory pathway. Furthermore, it was reported to affect 
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dendritic cell (DC) function via the induction of the immunosuppressive indoleamine 2,3 
dioxygenase (IDO) pathway, thus promoting a DC regulatory phenotype. Consequently, we 
studied immuno-regulation mediated by CTLA-4Ig in an allogeneic setting using C57BL/6 
splenic and bone marrow derived DCs as stimulators of allogeneic Balb/c T cells. We found 
that CTLA4-Ig potently dampened allogeneic T cell responses when present during T cell/DC 
co-culture. This dampening effect was neither related to the activation of the IDO pathway 
nor to the induction of a DC regulatory phenotype, but directly affected DC/T cell crosstalk 
and preferentially targeted the CD4+ T cell response. Moreover, CD4+ T cells recovered from 
those DC/T cell co-cultures yielded a T cell population with a high expression in 
CD25+CD62L+FoxP3+ suggesting a CTLA4-Ig mediated regulatory phenotype. Remarkably, 
this regulatory phenotype was preserved upon restimulation. 
In conclusion, CTLA4-Ig inhibits allo-stimulated T cells in an IDO independent fashion by 
modulating the allogeneic, proliferative T cell response while propagating a regulatory 
phenotype. Therefore, expanding regulatory T cells as mediated by CTLA-4Ig may open a 
new therapeutic window for successful T cell therapy during HSCT.  
 
9 
2 Introduction 
 
2.1 Hematopoietic stem cell transplantation 
 
Hematopoietic stem cell transplantation (HSCT) is a procedure in which pluripotent 
hematopoietic stem cells capable of reconstituting normal bone marrow functions are 
administered to a patient. In general, allogeneic HSCT is a powerful curative approach to treat 
patients suffering from congenital or acquired malignant and non-malignant diseases [1]. 
Selection of the type of transplantation depends on the type of malignancy, age of the 
recipient, availability of a suitable donor and the stage and status of the disease. In principle, 
HSCT aims to establish a long term and self-sustaining donor-type hematopoiesis in the 
recipient, so called chimerism [2]. The types of hematopoietic stem cells are categorized 
based on the source of progenitor cells used in the transplant. Currently, three sources of stem 
cells are distinguished: bone marrow, peripheral blood, or cord blood. Further, hematopoietic 
stem cells can be obtained from the patient himself (termed autologous transplant), from a 
genetically identical twin (syngeneic transplant) or from another human leukocyte antigen 
(HLA)-matched related or unrelated individual (allogeneic transplant) [3]. Each of these 
sources of cells has specific advantages and disadvantages, and each has found particular 
applications in the care of patients. For instance, patients receiving autologous transplants 
have a lower risk of life-threatening complications. Since there is no risk of GvHD in 
autologous transplantation, immunosuppressive therapies to prevent GvHD and graft rejection 
are not required. However, disease recurrence generally occurs less frequently in patients 
receiving allogeneic transplants than autologous ones. Furthermore, allogeneic transplants 
have the advantage to be free of contaminating tumor cells and may induce an immune graft-
versus-leukemia effect based on donor-derived immunocompetent cells [3].  
Prior to HSCT, recipients undergo an immunosuppressive conditioning by radiation and/ or 
chemotherapy with the purpose, to help eradicate the patient's disease prior to the infusion of 
hematopoietic stem cells, and to suppress immune reactions to allow for engraftment and to 
prevent rejection [4, 5]. Thereafter, donor bone marrow, or peripheral blood stem cells 
(PBSCs) from donors that have been treated with granulocyte colony-stimulating factor (G-
CSF) are infused [6]. Nevertheless, immunosuppression also sows the seed for negative side 
effects as a consequence of an inferior reconstituted immune system in the immediate post-
transplant period [7]. Hence, next to transplantation-associated toxicity and failure of 
engraftment [8], patients are highly susceptible for reactivation or exacerbation of 
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opportunistic infections. Further, graft recipients are prone to develop pathogenic allo-
reactions, particularly involving the T cell system in the direction of graft-versus-host disease 
(GvHD). All these possible complications implicate a high transplant-related morbidity and 
mortality (TRM) [9, 10] (Figure 1). 
 
 
Figure 1 The immune system after HSCT. 
During a prolonged period of immune suppression and dysregulation after HSCT the patient 
is at high risk for developing life-threatening opportunistic infections or GvHD since immune 
reconstitution is slow and functionally impaired (Jürgens B.; PhD Thesis University of 
Vienna; 2008).  
 
2.2 Immune reconstitution following HSCT 
 
The reconstitution of different cellular subsets of the immune system after an allogeneic 
HSCT occurs in a chronological manner. Cells representing the innate part of the immune 
system, e.g. monocytes, macrophages or natural killer cells, recover rapidly after HSCT [11]. 
Cells constituting the adaptive part of the immune system, take a longer time to quantitatively 
recover. Therefore, T- and B-cell responses will be incomplete for a prolonged post-transplant 
period. These days, a deficiency of B-cells within the first three months after transplantation 
can easily and effectively be replaced by pharmacologically prepared immunoglobulin [11]. T 
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cells, however, require several months after HSCT for quantitative reconstitution and even 
after T cell recovery, immunity is still imbalanced as a result of disturbed T cell function [11, 
12]. Particularly in the first weeks after surgery, the lymphoid system of transplant recipients 
contain altered compositions of T cell populations [13]. Whereas, CD8+ T cells propagate to 
normal or elevated levels three to six months after HSCT, CD4+ T cells increase slowly to 
return to normal levels e.g. in children within less than one year, where T cell reconstitution 
occurs more rapidly than in adults [14]. CD4+ T cell reconstitution is particularly slow in 
older patients because of poor thymic function [7] (Figure 2).  
Since mainly alloreactive T cells expand instead of the immunocompetent ones [15] patients 
are at a much higher risk to develop GvHD than to regain T cell-mediated protective 
immunity. To overcome this problem, pharmacological immunosuppression is essential in the 
post-transplant period. Consequently, T cells remain incapable of re-establishing normal 
functions, including immune competence to environmental pathogens and self-tolerance. 
To conclude, treatment-related circumstances of allogeneic HSCT result in profound and 
prolonged T cell deficiency. Impaired T cell function is a leading factor of TRM in the post-
transplant period. Thus, the problem of T cell regeneration remains a main immunological 
challenge after HSCT. 
 
Figure 2 Reconstitution of different cellular subsets of the immune system after 
allogeneic HSCT. 
Natural killer cells (NK), monocytes and B cells return rapidly to pre-treatment levels, 
whereas especially CD4+ T cells show a delayed recovery. Finally, a successful 
transplantation is characterized by reconstitution of full immunity and tolerance to the 
allogeneic graft (Hainz U.; PhD Thesis University of Vienna; 2005).  
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2.3 Patient’s risks in the early post-transplantation period 
 
2.3.1 Bacterial, viral and fungal infections 
 
Bacterial infections are common during the early post-transplant period, but are generally 
well controlled by the appropriate use of antibiotics. Viral and fungal infections are less well 
treatable by drugs and are therefore one of the main clinical burden apart from GvHD [16]. 
Viral infections, in particular infections with cytomegalovirus (CMV) and Epstein-Barr virus 
(EBV), are often reactivated after allogeneic stem cell transplantation. Therefore several 
attempts have been undertaken to support HSCT recipients with a specific T-cell 
immunotherapy against these viral diseases. Such include the generation of CMV- or EBV-
specific T effector cells in vitro and adoptively transferring these cells to the patients [17, 18]. 
However, since these T cells are only effective against target viral antigens, they are 
incompetent and/ or non-reactive against other infections, such as those mediated by fungi 
[18, 19]. 
 
2.3.2 Graft-versus-host disease (GvHD) 
 
GvHD is a complex disease caused by donor T cells which react against host allogeneic 
antigens in the immunosuppressed patient [20, 21]. As mentioned above, the therapeutic 
approach of HSCT is based on the deletion of the recipient’s hematopoietic system using 
chemotherapy and irradiation, and on its substitution by hematopoietic cells from a healthy 
donor. The donor graft contains both hematopoietic stem cells that are capable to durably 
reconstitute a complete hematopoiesis, and immunocompetent cells including T cells. This 
donor T cell compartment contains alloreactive cells which recognize host allo-antigens [22, 
23]. Basically, the development of GvHD can be divided into three sequential steps or phases 
[24]. In the first step (phase I), antigen-presenting cells (APCs) of the host organism are 
activated by the underlying disease and the conditioning regimen. Damaged host tissues 
respond by producing “danger” signals, including (i) proinflammatory cytokines (e.g. tumor-
necrosis factor (TNF)-α), (ii) chemokines and (iii) increased expression of adhesion 
molecules, MHC antigens and costimulatory molecules on host APCs [25, 26]. In the second 
step (phase II), donor T cells proliferate and differentiate in response to host APCs. This 
activation is augmented by the “danger” signals which were generated in phase I, at least 
partially, by increasing the expression of costimulatory molecules [26-28]. In the last step 
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(effector phase), cellular mediators (e.g. cytotoxic T lymphocytes and NK cells) and 
inflammatory mediators (e.g. TNF-α, interferon (IFN)-γ, interleukin (IL)-1 and nitric oxide) 
synergize to amplify local tissue injury and further promote inflammation and destruction of 
target tissues [27, 29]. 
 
In the clinical setting, GvHD is divided into acute and chronic forms. Acute GvHD is defined 
by occurring within 100 days post transplantation and is characterized by damage to the skin, 
liver and the gastrointestinal tract, whereas chronic GvHD has more diverse manifestations 
that can be similar to autoimmune syndromes [6]. Patients with acute GvHD are suffering 
from rash, jaundice, diarrhea, and gastrointestinal hemorrhage. When the epithelial cell 
damage is very extensive, the skin or lining of the gut are simply slough off and under these 
circumstances acute GvHD may be fatal [3, 30]. Acute GvHD is classified into grade I (mild), 
II (moderate), III (severe) and IV (very severe) which is determined by the extent of 
involvement of the three main target organs. Severe GvHD possesses a poor prognosis: 25% 
long term survival for grade III and 5% for grade IV [31]. Chronic GvHD normally occurs 
after day 100 post-transplantation. The emergence of chronic GvHD may be (i) progressive, 
when active or acute GvHD changes over to chronic; (ii) quiescent, when acute GvHD that 
was resolved completely is later followed by chronic GvHD or (iii) it may develop de novo. 
Besides, patients older in age are more prone to develop chronic signs of GvHD [32, 33]. 
Typical clinical signs of chronic GvHD are dry eyes, oral lesions, nail dystrophy, skin 
sclerosis as well as skin ulcers.  
 
The incidence of acute GvHD is most often related to the degree of mismatches between HLA 
(human leukocyte antigen) proteins of the donor and the recipient [34]. HLA proteins are 
encoded by the major histocompatibility complex (MHC), are highly polymorphic and are 
mainly divided into two classes. Class I HLA (A, B, and C) proteins are expressed on nearly 
all nucleated cells of the body to a distinct extent. Class II proteins (DR, DQ and DP) are 
predominantly expressed on hematopoietic cells such as B cells, dendritic cells and 
monocytes, but their expression is inducible following inflammation or injury on many other 
cell types [29, 35]. In spite of HLA identity between a patient and a donor, nearly 40% of 
patients receiving HLA-identical grafts develop acute GVHD. The reasons for this are genetic 
differences lying outside the HLA loci, termed “minor” histocompatibility antigens [34]. 
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Diverse strategies have been developed to support HSCT recipients with a specific T-cell 
immunotherapy in order to minimize unwanted and uncontrolled graft-versus-host immune 
reactions. Among these were clinical studies exploring T cell depletion (TCD) as a 
prophylaxis for GvHD. For the depletion of T cells three principal strategies were used: (i) 
negative selection of T cells ex-vivo, (ii) positive selection of CD34+ stem cells ex vivo, and 
(iii) anti-T cell antibodies in vivo [36]. 
Most strategies concerning ex-vivo TCD-therapy revealed that the emergence of both acute 
and chronic GvHD was significantly reduced. However, high rates of graft failure, relapse of 
malignancy, infections, and Epstein-Barr virus-associated lymphoproliferative disorders were 
observed [37-40]. The treatment of patients with anti-T cell antibodies before transplantation 
(in vivo TCD) aims to reduce the host immune response and thus promotes engraftment. 
Additionally, donor T cells are down-regulated since the antibody is still circulating at the 
time of transplantation and thus GvHD is prevented [41, 42]. However, side effects of anti-T 
cell antibody infusions are common and TRM remains unchanged because of a higher risk for 
lethal infections. Although all these approaches may have, at least, some success they 
exclusively focus on the issue of elimination but not on regulating allo-reactivity. 
Nonetheless, both these processes seem to be required for the generation of true 
transplantation tolerance [43]. 
One further strategy is to generate a regulatory T cell population from the donor prior to 
transplant by an ex vivo expansion of a CD4+CD25+ T cell population. These T cells in fact, 
when being transfused, have been shown to prevent GvHD [44-50]. Still, the specificity of 
regulation of GvHD by ex vivo expanded regulatory T cells (Tregs) seems to be a critical 
issue. In vitro studies revealed that, after activation, Tregs display a bystander suppressive 
effect on all conventional T cells (generally immunosuppressive activity) [51, 52]. This 
bystander suppression of Tregs could limit their capacity to prevent GvHD because of 
impaired immune reconstitution during the first months after HSCT. Yet, when recipient-
specific in vitro expanded Tregs were used, bystander suppression seemed to be limited (in 
contrary to polyclonally expanded Tregs) accompanied by significant immune reconstitution 
[47, 48]. 
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2.4 Tolerance 
 
In general, T cell tolerance is primarily achieved by the elimination of potentially self-reactive 
lymphocytes in the thymus through a mechanism termed negative selection (central 
tolerance). Nevertheless, some self-reactive lymphocytes may escape negative selection in the 
thymus and thus manage to enter peripheral tissues. Therefore, such self-reactive T 
lymphocytes are strictly controlled by peripheral tolerance including mechanisms. These 
mechanisms include the induction of anergy or apoptosis in self-reactive T lymphocytes either 
by regulatory T cells or regulatory APCs. The failure in inducing tolerance towards self-
antigens is the result for several menacing autoimmune disorders [3, 53]. 
 
The ultimate goal of allogeneic HSCT is to introduce chimerism in the recipient long term 
and self-sustaining, i.e. to create tolerance against recipient type self-antigens. Transplantation 
tolerance is defined by (i) the maintenance of a chimeric state without a pathologic immune 
reaction against the allo-antigens (ii) in the absence of pharmacological immunosuppression 
(iii) while preserving intact immune reactions against environmental antigens. 
As mentioned above, in HSCT T cells are the major effector component of the immune 
system and have the potential to direct alloreactivity towards rejection or GvHD or tolerance 
[54]. Therefore, it is a critical task of research in the field of HSCT to support the allo-HSCT 
recipient with T cells which are specifically tolerant against allo-antigens and retain their 
protective capability to control infections as long as the process of developing allo-antigen 
specific tolerance by nature is incomplete. The magic goal is to generate such T cells ex vivo 
and utilize these T cells for adoptive transfer strategies. 
 
Transplantation tolerance essentially involves two critical processes, (1) the deletion of 
alloreactive T cells as a first step and (2) the development of anergy and regulatory activity of 
alloreactive T cells [43]. Based on these demands, two approaches hypothetically would 
excellently satisfy these criteria and are currently probed: (i) the utilization of the tolerizing 
potential of the enzyme indoleamine 2,3-dioxygenase (IDO) or (ii) inducing allo-antigen 
specific tolerance via co-stimulation blockade. 
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2.5 Biological and biochemical background of IDO activity 
 
Tryptophan (TRP) is the least abundant of the essential amino acids in mammalians [55]. 
Since it cannot be synthesized by the human body from other components to sufficient levels, 
its availability depends on food intake. A small proportion of TRP (approximately 1%) is 
utilized for the synthesis of the neurotransmitter Serotonin. About 5% are used for protein 
synthesis and the remaining major proportion (~95%) is metabolized along the kynurenine 
pathway to end up in the production of the co-enzyme nicotinamide-adenine-dinucleotide 
(NAD). The processing of TRP to kynurenines is mediated by two different enzymes: 
tryptophan 2,3-dioxygenase (TDO) and IDO (Figure 3). TDO is a homeostatic enzyme 
mediating TRP degradation exclusively in the liver, whereas ubiquitously-expressed IDO is 
not restricted to specific organs and tissues and governs the levels of TRP in the human body 
[56]. However, whereas TDO’s activity is induced by TRP and metabolic steroids, IDO 
becomes activated in response to inflammatory signals. Therefore, IDO is detected, amongst 
others, in patients suffering from autoimmune diseases and in those recovering from 
transplantations [57-59]. Under such conditions, enhanced systemic IDO activity shifts the 
TRP equilibrium in the intercellular microenvironment towards lower TRP concentrations 
resulting in an accumulation of kynurenines influencing alloantigen-specific T cell responses 
[60]. 
 
Figure 3 Pathways of tryptophan catabolism. 
IDO and TDO initiate tryptophan catabolism by oxidative cleavage of the pyrrole ring of 
tryptophan.TDO activity occurs in the liver and is responsible for tryptophan degradationin 
steady state conditions. The enzymatic activity generates N-formylkynurenine that rapidly 
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converts into kynurenine. The downstream products of kynurenine shown in this graph have 
been described to possess immunosuppressive activity (Jürgens B.; PhD Thesis University of 
Vienna; 2008).  
 
Originally, IDO activity has been described as a host defense mechanism. Enhanced 
tryptophan degradation did deprive pathogens, such as Chlamydia or Toxoplasma, from their 
access to tryptophan and exposed them to toxic tryptophan metabolites in order to terminate 
infections [61, 62]. By the late 1990s, a study by D. Munn et al [63] showed that IDO activity 
was critically involved in the immunologic acceptance of semi-allogeneic fetuses in a murine 
model. This study has since fuelled a new understanding of IDO’s activity as a central 
pathway for dampening potentially dangerous immune reactions [60] including allo-antigen 
driven immunopathology.  
IDO expression combined with actively metabolized TRP was found in multiple APC types 
such as monocytes/macrophages [64], dendritic cells [65, 66] and even non-classical APCs, 
e.g. bone marrow stroma cells [67]. Importantly, they utilize the IFN- inducible enzyme 
tryptophanyl-tRNA-synthetase [68], which catalyzes the association of tryptophan with its 
specific tRNA, resulting in a tryptophan-tRNA. This complex provides a reservoir of TRP 
protected from IDO-mediated degradation and protects IDO-inducible cells from TRP self-
starvation. Some APCs may constitutively express IDO such as the murine CD8+ lymphoid 
DC subset [69]. In other types of APCs, expression of IDO is inducible by agents that are 
generally considered pro-inflammatory e.g. lipopolysaccharide (LPS), TNFα, a DC 
maturation cocktail containing TNF-α, IL-1ß/IL-6 and prostaglandin E2 (PGE2), and, most 
prominently, IFN-γ [66, 70].  
Since, IDO is induced by the same mechanisms and molecules that initiate immune activation 
[71, 72] it is thought to function as a feedback mechanism to counter-regulate or terminate 
potentially dangerous effector immune responses [73, 74]. Previous research suggested that 
B7 (CD80/ CD86)-engagement by the fusion protein CTLA-4Ig on murine DCs results in 
down-stream cellular signalling events leading to IDO activation that initiates the 
immunosuppressive pathway of tryptophan catabolism [74-76]. In detail a pathway was 
proposed in which CTLA-4Ig binding to CD80/86 of DCs elicits IFN-γ production which in 
an autocrine or paracrine fashion induces IDO to ultimately generate regulatory activity in 
DCs [71] (Figure 4). Further, it was reported that CTLA-4Ig functions in vivo in allogeneic 
islet transplant tolerance by triggering the production of functional IDO in APCs (Grohmann 
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et al., 2002). Subsequent studies proposed that in fact CTLA-4+, CD4+C25+ regulatory T cells 
might exert their effect by IDO induction in DCs [77]. 
 
Figure 4 Model of tolerance induction by B7-dependent signaling in DCs. 
CTLA-4-Ig-binding to the DCs induces Dc signaling via CD80/86 (B7-1/B7-2). In a signal 
transduction pathway that is dependent on STAT1, p38 MAPK and NFkB, the DC is 
stimulated to produce IFN-γ. IFN-γ acts in an autocrine or paracrine manner to promote 
upregulation of IDO which catalyses the degradation of TRP to kynurenines (Finger E.B. and 
Bluestone J.A.; Nature Immunology; 2002). 
 
Nevertheless, it has to be kept in mind, that IDO expression alone does not necessarily 
indicate IDO activity. In fact, IDO activity is tightly regulated by post-translational 
mechanisms. They may include an alteration of the enzyme’s heme-active binding site [78] 
possibly by an effect of nitric oxide (NO) [79, 80]. Pathways to counteract the effect of IDO 
on immune responses include CD40 ligation of lymphoid DC [81] by an IL-6 dependent 
mechanism [82].  
 
2.6 Mechanisms of IDO-mediated transplantation tolerance  
 
Allogeneic HSCT is intimately associated with a state of sustained immune activation, which 
invariably will emerge in HSCT recipients. Immune activation is driven by recognition of 
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major or minor histocompatibility antigens even in case of HLA-matched donors, but will 
also result from tissue damage caused by the conditioning regimens. This state of sustained 
immune activation will include the continuous secretion of pro-inflammatory cytokines 
(including IFN-γ) by APCs or activated T cells, which, in turn, will induce sustained IDO 
activity.  
 
In the current model of IDO’s immunosuppressive activity, IDO preferentially targets 
activated T cells [71]. Upon inflammation, IDO expression and activity is induced in APCs 
leading to enhanced tryptophan breakdown and accumulation of kynurenines in the 
microenvironment. Both features are influencing the immunoregulatory activity of 
alloantigen-specific T cells as follows. After the activation of antigen-specific T cells, the 
reduced levels of TRP and enhanced levels of kynurenines trigger the activated alloreactive T 
cells to undergo cell cycle arrest and apoptosis instead of mounting an effector immune 
response towards the alloantigen presented by the APC [60, 83, 84] (Figure 5). Therefore it 
was suggested that the T cell non-responsiveness induced by IDO-expressing APCs is 
alloantigen specific [85]. However, T cells that are not activated by the particular antigen 
presented by IDO-expressing APCs (resting T cells), may remain largely unaffected and thus 
should retain their immunological potential to induce adequate responses when subsequently 
challenged by normal APCs. 
 
Figure 5 Hypothetical antigen-specific activity of IDO. 
By concept, IDO competent antigen-presenting DCs exert their T cell suppressive effect 
particularly within the immunological synapse (dashed area), which is formed by a DC 
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derived MHC/antigen complex and a T cell receptor complex recognizing the antigen. The 
effects of IDO activity, namely low TRP concentration and high levels of TRP breakdown 
products (kynurenines) are focused in this microenvironment and therefore specifically affect 
antigen-specific T cells. These are arrested in cell cycle progression and are rendered 
susceptible to apoptosis. T cells that are not antigen-specific remain unaffected (Hainz U.; 
PhD Thesis University of Vienna; 2005).  
 
Correspondingly, employing IDO activity may represent an approach to generate alloantigen-
specific tolerance after HSCT [85] (Jürgens et al). It was shown that enhanced IDO activity is 
present in HSCT recipients [86] and possibly involved in modulation of GvHD [87].  Further, 
it has been shown that T cells exposed to IDO-expressing DCs acquire a T cell regulatory 
phenotype (high levels of expression of the CD25 cell surface molecule accompanied by 
intracellular expression of FOXP3) in murine [88] and human systems [85]. By these 
mechanisms IDO activity essentially meets the above mentioned criteria required for 
tolerance induction in transplantation [43] as it (i) selectively eliminates allo-reactive T cells 
by apoptosis and (ii) generates regulatory T cells. 
 
Together, IDO is a potential candidate to mediate transplantation tolerance as T cells activated 
by alloantigens under conditions of enhanced tryptophan metabolism become susceptible to 
apoptosis, leading to a quantitative reduction of alloreactive T cells. 
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2.7 Co-stimulation and co-stimulation blockade 
 
T lymphocytes play a central role in the initiation and regulation of the adaptive immune 
response to antigens, whether foreign or native. T cell activation is tightly regulated, including 
essentially the signaling via T cell co-stimulation receptors.  
In general, naïve T cells require two signals for their full activation [89]. The first signal 
(Signal 1) is an antigen-specific one, provided by the T cell receptor when it recognizes and 
interacts with a specific antigen that is presented in MHC-antigeneic peptide-complexes on 
the surface of APC. The second signal (Signal 2), termed co-stimulatory signal, is supplied by 
the interaction between specific receptors (co-receptors) on the T cell and their ligands on the 
APC [90, 91]. Together, both signals synergize in activating a number of down-stream 
cellular signaling pathways leading to optimal cytokine production, proliferation, effector 
function and survival [92]. Co-stimulation alone in the absence of signal 1, generally leading 
to T cell receptor stimulation has no effect on the T cell. Furthermore, if a T cell receives 
signal 1 without a co-stimulation signal, T cell unresponsiveness or anergy (antigen specific 
unresponsiveness) is induced [93]. 
 
The blockade of signaling through co-stimulation receptors with the use of specific co-
stimulation inhibitors, enables the selective prevention of T cell responses and has the 
potential of inducing tolerance to specific antigens in both autoimmunity and transplantation 
[94-97]. Hence, co-stimulation blockade has become of great interest in the field of 
transplantation being used as an immunosuppressive therapy. Co-stimulation blockers are 
main candidates for such clinical approaches. Some of them have proved successful in being 
used as maintenance therapy replacing current drugs that require frequent therapeutic drug 
monitoring and are associated with severe side effects and chronic toxicities [98]. 
 
Multiple co-stimulatory pathways are involved in the regulation of T cell activation which 
may function either to augment or attenuate antigen-specific T cell responses. These include 
(i) the CD28-CD80/86 pathway, (ii) the CD40/CD154 pathway and (iii) the LFA-1/ICAM 
pathway. Among these, co-stimulatory interactions between the homodimer CD28 and its 
ligands CD80 and CD86 of the B7 family have been reported as the most critical and certainly 
the best characterized one’s [99, 100]. 
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2.7.1 CD40/CD154 and LFA-1/ICAM pathways – a short overviw 
 
The CD40/CD154 pathway was originally described to play a pivotal role for B cell activation 
and isotype class-switching, as well as for DC activation and maturation. Later on, this 
pathway was reported to contribute to T cell activation by upregulating MHC molecules and 
the co-stimulatory molecules CD80 and CD86 on APCs [101, 102]. More precisely, CD40 
and its only known ligand CD154 (also termed CD40 ligand; CD40L) are members of the 
TNF and tumor necrosis factor receptor (TNFR) superfamily [103, 104]. Whereas CD40 is 
constitutively expressed on APCs (such as B cells, macrophages, DCs), CD154 is induced on 
the surface of T cells upon activation [103]. The interaction between CD40 and CD154 
initially provides co-stimulatory signals to APCs rather than to T cells. Signaling via CD40 is 
mediated by specific adapter proteins, so called TRAFs (tumor necrosis factor receptor-
associated factors) for which the cytoplasmic tail of CD40 contains the respective binding 
sites and leads to the activation of the transcription factor NFκB and to the induction of 
NFκB-responsive pathways [105, 106]. This in turn leads to an upregulation of MHC 
molecules and of the co-stimulatory molecules CD80 and CD86, enhanced DC survival and 
increased production of inflammatory cytokines such as IL-12 and TNF. Taken together, 
CD40 signaling results in mature APCs that are more powerful to promote effective T cell 
responses due to augmented antigen presentation and co-stimulation. Additionally, a poorly 
defined CD40L signal to the T cell might occur but the importance of this signal for the T cell 
remains largely unclear. 
 Lymphocyte function-associated antigen 1 (LFA-1) is a member of the integrin family and is 
constitutively expressed on all T cells at either low or high surface densities. Further it is also 
found on B cells, macrophages and neutrophils. LFA-1 is a ß2 integrin consisting of two 
chains, (i) a unique alpha chain (CD11a) and (ii) a beta chain (CD18) which is common to 
other ß2 integrins. LFA-1 interacts with ICAM-1 (intracellular adhesion molecule 1) which is 
expressed on APCs and thereby functions as an adhesion molecule [3]. Thus, LFA-1 plays an 
important role in stabilizing contacts between T cells and APCs and ensures optimal 
activation of T cells. In addition to its adhesive functions, LFA-1 delivers, through its 
interaction with ICAM-1, co-stimulatory signals that are important for T cell activation and 
cytotoxic T cell function [107, 108]. 
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2.7.2 Molecular mechanisms underlying the CD28-CD80/86 pathway 
 
The CD28 receptor is known to be constitutively expressed by a majority of CD4+ T cells in 
mice and humans but was reported to be only expressed by approximately 50% of murine 
CD8+ T cells [109]. It seems that those CD8+ CD28 negative T cells might act independently 
of co-stimulation or use other co-stimulatory pathways to get fully activated [110]. The 
homodimer CD28 interacts through a specific recognition motif (MYPPPY) in its 
extracellular domain with CD80 and CD86 of APCs [111]. In contrast to CD28, the co-
stimulatory molecules CD80 and CD86 are generally expressed, if at all, at very low levels on 
resting APCs, such as dendritic cells, macrophages and B cells. However, upon cellular 
activation CD80 and CD86 co-stimulatory molecules undergo remarkable upregulation. Both 
B7 molecules exhibit similar Ig-like extracellular domains and short cytoplasmic tails, while 
sharing only approximately 26% total sequence identity. Nevertheless, CD80 and CD86 have 
distinct but overlapping functions. While CD86 may be important in mediating initial T cell 
activation, CD80 may play a greater part in perpetuating the immune response [110, 112]. 
The interaction of CD28 with CD80/ CD86, together with signaling through the T cell 
receptor (signal 1), promotes the expansion (signal 2) of antigen-stimulated T cells and their 
differentiation into effector and memory cells. Additionally, CD28 signalling leads to 
enhanced production of cytokines (especially IL-2), upregulation of cell survival genes (such 
as Bcl-xL) and enhanced cell cycle progression (Figure 6, middle panel). After T cell 
activation, the upregulation of a second receptor, termed cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4) is induced [113]. The homodimer CTLA-4 is structurally homologous to 
CD28 and also binds to CD80 and CD86 ligands via a MYPPPY recognition motif but with a 
higher affinity than CD28. Additionally, each CTLA-4 dimer is able to bind two different B7 
homodimers, thereby forming a stable lattice-structure with B7 molecules [114]. This highly 
enhances the affinity (stability) of CTLA-4:B7 interactions [115]. However, this structure is 
not seen in the case of CD28, which can only interact with a single B7 dimer at a time [114]. 
Unlike CD28, CTLA-4 is a negative regulator for T cell activation and once upregulated, it 
successfully competes for CD80 and CD86 ligands and thus turns off T cell activation [116, 
117]. T cell proliferation is downregulated by inhibiting IL-2 production and blocking cell-
cycle progression (Figure 6, bottom panel). The important role of CTLA-4 as a negative 
regulator for T cell activation is reflected in the phenotype of CTLA-4–deficient mice. It was 
reported, that these mice develop severe lymphoproliferation and autoimmunity and die 
within a few weeks after birth. Because of CTLA-4 deficiency, T cells are prevented to 
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undergo cell cycle arrest. This leads to an increased accumulation of activated T cells which 
ultimately infiltrate vital organs causing animal death [118, 119]. 
 
 
 
Figure 6 Roles of the B7-CD28/CTLA-4 pathway in the regulation of T cell activation 
Resting APCs express low or no B7-1/B7-2 (CD80/ CD86) co-stimulatory molecules and are 
unable to activate naïve T cells (top panel). Upon activation APCs stimulate the expression of 
B7 co-stimulatory receptors. Interactions of B7 co-stimulatory molecules with CD28 
receptors of the T cell lead to expansion and differentiation of naïve T cells (middle panel). 
The CTLA-4 receptor, which has a higher affinity to B7-1 and B7-2 co-stimulatory molecules 
than CD28 is upregulated on activated T cells. Interactions of B-7 molecules of activated 
APCs with the CTLA-4 T cell receptor inhibit T cell responses (bottom panel) (Sharpe A.H.; 
New England Journal of Medicine; 2006). 
 
2.7.3 Therapeutics designed to inhibit CD28-mediated co-stimulation 
 
Throughout the 1990s several attempts have been undertaken to inhibit CD28-mediated co-
stimulatory signalling with the purpose to induce tolerance to treat autoimmune disease as 
well as to prevent graft rejection or graft-versus- host disease.  
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One strategy of blocking CD28-mediated signals resulted in the development of anti-CD80/ 
CD86 monoclonal antibodies with the intent to induce anergy in vitro or tolerance in vivo. For 
example in a human in vitro model, allo-anergy was induced in donor T cells by ex-vivo 
stimulation with allogeneic recipient APCs in the presence of humanized anti-CD80 and anti-
CD86 monoclonal antibodies [120]. These antibodies were generated to bind both CD80 and 
CD86 co-stimulatory molecules with similar avidity and kinetics leading to an inhibition of 
allogeneic responses of both CD4+ and CD8+ T cells. In addition, the ability of CD4+ and 
CD8+ T cells to respond against viral infections (such as human herpes virus) was preserved. 
Furthermore, transplantation of such ex-vivo generated allo-anergized T cells revealed 
promising success in a phase 1 clinical study of haploidentical bone marrow transplantation 
with an acceptable engraftment and a lower outcome of viral infections and acute GvHD 
[121]. Furthermore, the use of such anti-CD80/ anti-CD86 antibodies has also proved 
successful to induce tolerance in solid organ transplantations as reviewed in Ford and Larsen 
2009 [122]. Accordingly, it was shown in a non-human primate model that renal allograft 
rejection was delayed even in the absence of additional conventional therapies (calcineurin 
inhibitors (CNIs) or steroids) [123, 124]. This promising observation was further confirmed in 
a phase I clinical trial, where these monoclonal antibodies were safely applied as part of a 
combination immunosuppressive therapy [125]. 
Another concept to block CD28-mediated co-stimulatory signaling is to selectively target the 
CD28 receptor. This approach was assumed to be very beneficial in inhibiting immune 
responses since it was designed to specifically block CD28-mediated signaling while leaving 
inhibitory signals, triggered by the interaction of CTLA4 and CD80/CD86, intact. Using 
monoclonal antibodies targeting the CD28 receptor in vitro lead to a direct blockade of CD28 
and could effectively inhibit allogeneic T cell proliferative responses in a mixed lymphocyte 
reaction. Furthermore, short- term administration of anti-CD28 mAbs was reported successful 
in rodent models of renal transplantation in preventing allo-graft rejection [126]. Accordingly, 
co-stimulation blockade using a specific anti-CD28 mAb in a fully MHC-mismatched mouse 
model of BMT successfully inhibited the expansion of alloreactive donor T cells and thus 
prevented GvHD [127]. However, most antibodies to CD28 are agonistic or superagonistic 
and therefore, when bound to the specific receptor, are able to initiate CD28-mediated 
signaling into the cell even in the absence of a TCR-signaling complex (Signal 1). 
Correspondingly, the application of a specific superagonistic anti-CD28 mAb in a human 
phase I clinical trial caused a systemic inflammatory response in six healthy volunteers 
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resulting in a multiorgan failure, while supporting the expansion of regulatory T cells in 
preclinical studies [122]. 
 
2.7.4 The fusion protein CTLA-4Ig: potent inhibitor of CD28-mediated T cell co-
stimulation 
 
Another strategy to counteract CD28-induced T cell co-stimulation is mediated by 
recombinant CTLA-4Ig [96, 128, 129]. In general, CTLA-4Ig is structurally based on natural 
CTLA4 as it is composed of human or mouse CTLA4 fused to human or mouse IgG, 
respectively. The resulting chimeric protein is soluble, forms homodimers and acts as a CD28 
analogue featuring a much higher affinity to CD80/ CD86 present on APCs than CD28. 
Therefore, CTLA4-Ig effectively interferes with the binding of CD28 to B7 ligands, which 
results in the inhibition of CD28-mediated T cell co-stimulation leading to T cell anergy 
(Figure 7). Further specific modifications to CTLA-4Ig have been introduced by the company 
“Bristol Myers Squibb” by fusing the extracellular domain of CTLA4 to human Fcγ1 (Fc 
portion of IgG1) – known under the conventional name “abatacept”, or “Orencia”. 
 
 
 
Figure 7 CTLA-4Ig as a potent inhibitor of CD28-mediated T cell co-stimulation  
(Vincenti F.; J Allergy Clin Immunol; 2008) 
 
In clinical models, CTLA-4Ig was successfully tested in the treatment of autoimmune 
diseases including rodent models of encephalomyelitis, multiple sclerosis, autoimmune 
diabetes, collagen-induced arthritis, autoimmune glomerulenephritis and in several 
transplantation models, reviewed in [130]. In these transplantation models, application of 
recombinant CTLA-4Ig supported engraftment and graft survival, the induction of donor-
recipient chimerism and donor-specific tolerance, while reducing GvHD in the absence of 
immunosuppressive regimen [130]. Furthermore, treatment with CTLA-4Ig prevented the 
development of anti-donor antibody and T cell responses and resulted in a long-term survival 
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of islet, cardiac, and renal allografts in murine models, reviewed in [122]. As “abatacept” has 
been successfully used as an immunosuppressive regimen in a clinical trial for the auto-
immune disease rheumatoid arthritis it was approved by the US “Food and Drug 
Administration” (FDA), reviewed in [131]. 
Unexpectedly, the positive effects of administered chimeric CTLA-4Ig during transplantation 
could not be reproduced in studies using the more robust model of allogeneic renal 
transplantation and pancreatic islet transplantation in non-human primates resulting in only 
modest prolongation in allograft survival [132, 133]. One explanation was proposed due to 
the fact that “abatacept” is leaky in its ability to suppress CD28-mediated T cell stimulation 
since it features a lower avidity to CD86 compared with CD80 [134]. Therefore two 
additional mutations have been included to synthesize recombinant “belatacept” (originally 
termed “LEA29Y”, Bristol-Myers Squibb) that shows increased binding affinity to both B7 
molecules providing more potent immunosuppressive properties required for transplantation 
[135, 136]. However, one has to mention that “belatacept” just showed better results than 
“abatacept” in non-human primate studies while being inefficient in targeting murine B7 as 
reviewed in Pree 2006 [137]. 
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3 Working hypothesis 
 
This project addresses our continuing interest in the generation of allo-antigen tolerized T 
cells, particularly in the context of HSCT. The capability to ex vivo generate donor T cell 
populations, which are tolerant towards recipient allo-antigens but retain immune activity 
against pathogenic microorganisms, may provide recipients of HSCT with immunological 
broadly competent T cell immunity without aggravating the risk of GvHD as long 
endogenous T cell reconstitution is insufficient. Based on the conceptual view of IDO and the 
promising findings made by utilizing co-stimulation blockade and the recently proposed link 
between the two, we explored the following hypothesis: Immunological tolerance can be 
achieved using CTLA-4Ig treated and IDO competent DCs as stimulators of allogeneic T 
cells. 
 
 
 
We address this hypothesis in a murine model by co-culturing Balb/c derived donor T cells in 
an in vitro cell culture (MLR) with C57BL/6 derived recipient DCs that were induced to 
express functional IDO before co-culture. By concept, high IDO activity will deplete the 
essential amino acid TRP and accumulate TRP metabolites, such as kynurenines in the 
microenvironment, thus inducing tolerance in allo-reactive T cells either by depletion 
(induction of apoptosis in activated T cells) or by regulation (inhibition of allogeneic T cell 
proliferation or promotion of Tregs) while leaving resting T cells unaffected. Such in vitro 
manipulated T cells can be safely transferred to recipient mice of HSCT and are supposed to 
effectively transfer T cell immunity while not inducing GvHD. 
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4 Materials and Methods 
 
4.1 Mouse strains 
 
Female C57BL/6 (H-2b), Balb/c (H-2d) and DBA/2J (H-2d) mice were purchased from 
Charles River Laboratories (Sulzfeld, Germany). All mice were maintained under specific 
pathogen-free conditions at the Biomedical Research Institute, Medical University of Vienna 
(Vienna, Austria) and were used at 6 to 10 weeks of age. All experiments were performed 
according to a protocol approved by the local review board of the Medical University of 
Vienna and were accomplished in accordance with national and international guidelines of 
laboratory animal care. 
 
4.2 Cell culture 
 
Isolated mouse cells were cultured in IMDM medium (Invitrogen, Carlsbad, USA) containing 
2 mM L-glutamin and 25 mM Hepes supplemented with 10% (v/v) heat-inactivated fetal 
bovine serum (PAA clone; PAA Laboratories, Pasching, Austria), 100 U/mL penicillin/ 100 
µg/mL streptomycin (PAA-Laboratories) and 50 µM 2-mercaptoethanol (Sigma-Aldrich, St. 
Louis, MO) - hereafter termed complete medium, in a humidified incubator containing 5% 
CO2 at 37°C. 
 
4.2.1 Reagents for cell culture 
 
Murine recombinant IFN-γ was purchased from BD Pharmingen. hCTLA-4Ig (abatacept) 
consisting of the extracellular domain of human CTLA-4 linked to a fragment (hinge-CH2-
CH3 domains) of the Fc portion of human IgG1 [138, 139]  was generously provided by 
Bristol-Meyers, Squibb Pharmaceuticals (Princeton, NJ). Recombinant mouse cytolytic 
CD152/Fc chimera, a soluble dimeric fusion protein engineered by fusing the extracellular 
domain of mouse CD152 (CTLA-4) to a mouse mutant IgG2a Fc domain was purchased from 
Sigma and in this study termed CTLA-4Ig(S). 
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4.3 Techniques of cell preparation and stimulation 
 
4.3.1 DC generation 
 
DCs were generated from total splenic cells or from bone marrow precursor cells of 6 - to 10 
week old female C57BL/6 wt mice. The quality of DC generation was monitored 
microscopically every other day for a typical DC morphology. A classical DC phenotype, 
defined by expression levels of the cell surface markers CD11c, CD11b, MHC class I and II, 
CD80 and CD86, was determined by flow cytometric analysis. 
 
Generation of splenic DCs 
Splenic DCs were obtained from collagenase-treated spleens (Collagenase type IV from 
clostridium histolyticum, Sigma-Aldrich). Purification of DCs was performed according to 
previously described protocols [74, 81, 82, 140-143] as well as according to personal 
recommendations of Fallarino F. The two purification procedures used and described below, 
led to comparable results when cells were assayed in parallel in in-vitro experiments. 
 
Preparation of splenic DCs by gradient centrifugation followed by adherence 
Spleens (normally 5) were collected in a cell culture Petri dish (90x20mm; IWAKI, Japan) 
and air dried for a short time (1-2 min). For collagenase treatment 100 U/mL and 400 U/mL 
collagenase were prepared in 1x HBSS (Sigma). 1 mL of the 100 U/mL collagenase solution 
was injected into each spleen and effluent cells were collected with a syringe. Cell culture 
plates were washed with 5 mL IMDM complete medium to neutralize collagenase and spleens 
were then overlaid with 5-10 mL of the 400 U/mL collagenase solution. Collagenase-treated 
spleens were digested for 30 min at 37°C. After the incubation period, cell culture plates 
including the spleens were washed with IMDM complete medium to neutralize collagenase 
and digested spleens were smashed with a plunger and made into a single cell suspension by 
pressing through a 70µm sterile cell sieve (Falcon; DB Labware, Franklin Lakes, NJ). Total 
spleen cells were recovered by centrifugation at 1300 rpm for 8 min, the cell pellet was 
resuspended in MACS buffer containing 2 mM EDTA (pH 7.2) (Miltenyi) to disrupt DC-T 
cell complexes and cells were recovered by another centrifugation step. Cells were suspended 
in a 50% (p = 0,609) isoosmotic Nycodenz solution (Sigma-Aldrich), overlaid with medium 
and centrifuged at 3000 rpm for 15 min at 4°C. The low density fraction at the interface was 
collected and washed several times. The recovered cells were resuspended in IMDM complete 
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medium, collected in a cell culture Petri dish and allowed to adhere for 1.5-2 hours at 37°C. 
After the adherence step, the cell culture plates were thoroughly washed several times to 
remove non-adherent cells. The remaining adherent cells were provided with fresh IMDM 
complete medium and incubated for an addition of 18 h at 37°C to allow DCs to detach. The 
recovered cells were routinely 80 +/-10% positive for CD11c+ expression and consisted of 90-
95% CD8α- and 5-10% CD8α+ cells. 
 
Purification of splenic DCs by Magnetic Cell Sorting (MACS) 
DCs were purified according to CD11c expression using positive selection columns in 
combination with CD11c MicroBeads (MACS; Miltenyi Biotec, Bergisch-Gladbach, 
Germany) according to the manufacturer’s protocol. Briefly, collagenase-treated spleens were 
digested for 30 min at 37°C and made into a single cell suspension as described above. Total 
spleen cells were recovered by centrifugation at 1300 rpm for 8 min. The cell pellet was 
resuspended in sterile cold Erythrocyte lysis buffer (consisting of 0.15 M NH4Cl, 10 mM 
KHCO3, 0.1 mM Na2EDTA.; pH 7.2-7.4) for 2-5 min at room temperature (RT) to remove 
red blood cells and cell clusters were disintegrated by vigorous pipetting. After another 
centrifugation step (1300 rpm; 8 min) the cell pellet was resuspended in cold MACS buffer 
(pH 7.2) and 1mg/ 500µL labeling volume mouse IgG (Sigma-Aldrich) was added to the cell 
suspension to block Fc receptor-mediated magnetic labeling followed by addition of CD11c 
MicroBeads (100µL/ 108 total cells) for 15 min at 4°C. Then, the magnetically labelled cell 
suspension was loaded onto a MACS column, which was placed in the magnetic field of a 
MACS separator. The magnetically retained CD11c+ cells were eluted as the positively 
selected cell fraction. The recovered cells were routinely >90% CD11c+ and consisted of 90-
95% CD8α- and 5-10% CD8α+ cells. 
 
Isolation of CD8α+ DC subpopulations was performed in a two-step procedure using the CD8+ 
Dendritic Cell Isolation Kit (MACS; Miltenyi Biotec) according to the manufacturer’s 
instructions. In brief, single cell suspensions of collagenase treated spleens were prepared as 
described above. First, single cell suspensions were depleted of T cells, B cells, and NK cells 
by indirect magnetic labeling with a cocktail of biotin-conjugated Abs against CD90.2 
(Thy1.2), CD45R (B220) and CD49b (DX5) and Anti-Biotin MicroBeads followed by 
separation over a MACS column. In a second step, the flow-through fraction containing the 
pre-enriched dendritic cells was labelled with CD8a (Ly-2) MicroBeads and CD8α+ DCs were 
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isolated by positive selection. The recovered cells were >90% positive for CD11c+ and 
CD8a+. 
 
4.3.2 Generation of bone marrow derived dendritic cells (BMDCs) 
 
DCs were generated from mouse bone marrow according to an established protocol [144] 
with minor modifications. Briefly, femora and tibiae of 6- to 10 week old female C57BL/6 wt 
mice were dislodged and remaining tissue and muscles were removed with sterile gauze. The 
bones were sterilized with 70% (v/v) EtOH in a cell culture Petri dish (90 x 20mm; IWAKI) 
for 1 minute, air dried and put into IMDM medium (Invitrogen). Both ends of the bones were 
cut with sterile scissors, and bone marrow was flushed with IMDM medium from femora and 
tibiae using a syringe and a 27G ¾ needle (0.40 x 20 mm; Sterican; B.Braun, Bethlehem, PA, 
USA). The bone marrow cells were centrifuged at 1300 rpm for 8 min. and the pellet was 
resuspended in sterile cold Erythrocyte lysis buffer (pH 7.2-7.4) for 2-5 min at RT. The bone 
marrow was washed twice, and cell pellets were gently resuspended in IMDM complete 
medium. The cell number was determined on a Coulter Particle and Size Analyzer (Coulter 
Electronics Ltd., UK) and cells were plated in 6-well culture plates (IWAKI) at a 
concentration of 2,5x106 per well (5 mL/well). Immature DCs were generated by culture in 
complete IMDM medium supplemented with 5 ng/mL recombinant mouse IL-4 (BD 
Pharmingen) and 3 ng/mL recombinant mouse GM-CSF (BD Pharmingen) for 6 days. Half of 
the medium (including all supplements) was replaced every 2nd day to remove non-adherent 
granulocytes, whereas clusters of developing DCs remained loosely attached. On day 6 of the 
culture, non-adherent and loosely adherent DC aggregates were gently harvested for analysis 
or stimulation procedures. Immature BMDCs were highly positive for CD11c and CD11b (> 
80%) and showed low expression levels of MHC class I/II and CD80/CD86. 
 
4.3.3 DC activation 
 
Splenic DCs were plated in 24-well culture plates (IWAKI) at a concentration of 1x106/mL 
per well and exposed to the indicated concentration of 40 µg/mL CTLA-4Ig (IgG1a or IgG2a 
tails) or 200 U/mL IFN-γ for 24h. At the end of the stimulation period cells were harvested, 
phenotypically analyzed and used for subsequent experiments. 
Bone marrow derived immature DCs were plated in 24-well culture plates (IWAKI) at a 
concentration of 1x106/mL per well and exposed to a previously optimized concentration of 
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100 ng/mL LPS (Calbiochem; Escherichia coli O111:B4) with or without 20 ng/mL IFN-γ 
[144] for 48h hours. At the end of the activation period cells were harvested, phenotypically 
analyzed and used for subsequent experiments. This DC activation resulted in the 
upregulation of the surface markers MHC class I/II and CD80/86. 
 
4.3.4 CD3+ T lymphocyte isolation 
 
CD3+ T cells were isolated from spleens of wt Balb/c mice by magnetic cell sorting (negative 
selection) using the Pan T Cell Isolation Kit (MACS; Miltenyi Biotec) according to 
manufacturer’s instructions. Briefly, spleens were made into a single cell suspension as 
described above. Total spleen cells were recovered by centrifugation at 1300 rpm for 8 min 
and red blood cells were lysed in a hypotonic buffer (pH 7.2-7.4) for 2-5 min at RT as 
mentioned above. Cells were washed, recovered by centrifugation and resuspended in cold 
MACS buffer (pH 7.2). Non-T cells were indirectly magnetically labelled with a cocktail of 
biotin-conjugated Abs against CD11b (Mac-1), CD45R (B220), DX5 and Ter-119 as well as 
Anti-Biotin MicroBeads. The magnetically labelled non-T cells were depleted by retaining 
them on a MACS column, placed in the magnetic field of a MACS separator. Unlabelled T 
cells passed through the column and could be collected. This procedure resulted in greater 
than 95% enrichment of the targeted cell population. The purity and viability of the enriched 
T cells was evaluated by flow cytometry. 
 
4.3.5 T cell stimulation and mixed lymphocyte reaction 
 
Highly purified total CD3+ T cells (1 x 105) were co-cultured with allogeneic DCs (1 x 104) 
for 3 to 6 days in 96-well round bottom plates (NUNC; Thermo Fisher) in triplicates in a total 
volume of 200 µL IMDM complete medium per well (mixed lymphocyte reaction; MLR). In 
some experiments, DC/T cell co-cultures were performed in 24-well plates (IWAKI) in a 1:10 
DC to T cell ratio (1 x 105 DC and 1 x 106 T cells) in a total volume of 1.1 mL IMDM 
complete medium per well. Where indicated, CTLA-4 Ig (100µg/mL; IgG1a or IgG2a fusion) 
was added to the MLR on day 0 and thus for the whole culture period [145].  
For DC independent proliferation assays, CD3+ T cells (1 x 105) were cultured in 96-well 
round bottom plates coated with 3 µg/mL anti-CD3 (145-2C11) and 1 µg/mL anti-CD28 
(37.51) (BD Biosciences) in triplicates in a total volume of 200 µL per well for 48 hours.  
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T cells were stained with carboxyfluorescein succinimidyl ester (CFSE) (Sigma) according to 
a previously described protocol [146]. Briefly, T cells were washed with 1 x PBS and 
resuspended in 1 x PBS containing 0.1%BSA at a concentration of 1x107 cells/ mL. Cells 
were stained with 5µM CFSE for 10 min at 37°C followed by short blocking with fetal bovine 
serum. Afterwards, cells were washed twice with IMDM complete medium and stored on 
37°C until further use. Proliferative response was assessed by flow cytometric analysis of 
CFSE dilution. Where indicated, the “FlowJo Proliferation Platform” (Tree Star, Inc.) was 
used to analyze T cell proliferation, where “Percent divided” is defined as the percentage of T 
cells in the starting population that divided (assuming that no cells died during the culture). 
Percentage of inhibition was calculated by comparing the percentage of CFSE-negative T 
cells in co-cultures performed in the absence of CTLA-4Ig  to co-cultures in which CTLA-4Ig 
was present according to the following formula: Percentage of inhibition = [1- (percentage of 
CFSE- T cells in co-cultures with CTLA-4Ig / percentage of CFSE- T cells in co-cultures 
without CTLA-4Ig)] x 100. 
 
4.4 Techniques of analyses 
 
4.4.1 Flow cytometry 
 
Flow cytometric analyses were performed by using a FACSCalibur or a BD LSR II flow 
cytometer (BD Biosciences) and the list mode data were analyzed using either DivaCell (BD 
Biosciences) or FlowJo (Tree Star, Inc.) software. Cell staining procedure was performed 
according to standardized methods in our laboratory. In brief, 1 x 105 cells were washed in 1 x 
PBS (Invitrogen), recovered by centrifugation (1300 rpm; 8 min) and resuspended in 30µL 
purified anti-CD16/32 (mouse, clone 2.4G2, BD Pharmingen) diluted 1:100 in 1 x PBS for 10 
min at 4°C to block unspecific binding via Fcγ receptors. Tested amounts of the respective 
fluorochrome-coupled mAbs were added and samples were incubated for 30 min at 4°C. After 
an additional washing step with 1 x PBS (1300 rpm; 8 min), the supernatant was discarded 
and the cells were immediately analyzed by flow cytometry. The viability of the cells was 
determined by addition of DAPI (4',6 Diamidino-2-phenylindoldihydro-chlorid) shortly 
before measurement. Appropriate isotype control antibodies were included in the analyses.  
The following FACS antibodies were used: unconjugated anti-CD16/32 (2.4G2), FITC-anti-
H-2D[b] (KH95), PE-anti-I-A[b] (AF6-120.1), PE-CyTM7-anti-CD11c (HL3), APC-CyTM7-
anti-CD11b (M1/70), PerCP-anti-CD8a (53-6.7), APC-anti-CD3 (145-2C11), PerCP-anti-
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CD4 (RM4-5), APC-Cy7-anti-CD8a (53-6.7), PE-CyTM7-anti-CD25 (PC61), FITC-anti-H-
2D[d] (34-2-12), PE-anti-B220 (RA3-6B2), APC-anti-CD8a (53-6.7) (all from BD 
Biosciences), PerCP/Cy5.5-anti-CD80 (16-10A1), Alexa Fluor® 700-anti-CD86 (PO3), FITC-
anti-CD62L (MEL14), APC-anti-CD90.2 (30-H12) (all from BioLegend, San Diego, CA). 
For intracellular staining of FoxP3 in T cells, the Alexa Fluor 647 anti-mouse/rat/human 
FOXP3 Flow Kit (BioLegend) was used according to the manufacturer’s protocol. 
 
4.4.2 Enzyme-linked Immunosorbent Assay (ELISA) 
 
For examination of IFN-γ cytokine secretion, cell culture supernatants of DCs were analyzed 
by ELISA technique with the use of the BD OptEIATM Mouse IFN-γ ELISA Set (BD 
Biosciences). Cell culture supernatants were centrifuged (1300 rpm; 5 min) to remove any 
particulate material and samples were stored at -20°C or immediately used. The assay 
procedures were performed exactly as recommended by the manufacturer’s protocol. 
 
4.4.3 Immunoblotting 
 
IDO protein expression in DCs was investigated by immunoblot analysis. For the preparation 
of protein extracts from different dendritic cell cultures, cells (5 x 105-1 x 106) were 
harvested, washed twice in cold 1 x PBS and lysed by addition of 50 µL per 1 x 106 cells 
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% 
sodium deoxycholate, 150mM NaCl, 1mM EDTA) supplemented with protease inhibitors 
(Complete Protease Inhibitor Cocktail Tablets, Roche Diagnostics GmbH, Germany) for 10 
min at 4°C. After a centrifugation step, SDS sample buffer (20% Glycerin; 0.125M Tris-HCl; 
6% 2-mercaptoethanol; 3% SDS; bromphenole-blue) was added to the supernatant containing 
the whole cell lysates and proteins were denaturated for 5 min at 95°C. After cooling on ice, 
the samples were either used immediately for analyses or frozen at -20°C until use. Protein 
samples were fractionated on a 10% SDS-polyacrylamide gel for 90 min at 60 mA and 
transferred to a nitrocellulose membrane (Millipore Corp., Bedford, MA, USA) using a tank 
blot unit (BioRad Laboratories, Hercules, CA, USA), strictly working with cold buffers and 
blotting on ice at 300 mA for 60 min. As molecular mass standard a pre-stained protein 
marker (BenchMarkTM Pre-Stained Protein Ladder (6-180 kDa); Invitrogen) was used. In 
order to control the efficiency of blotting, membranes were reversibly stained with 1x 
PonceauS Red (Sigma). After ordinary washing with A.d and 1 x PBST (0.1% Tween), 
36 
membranes were blocked for 1 hour at RT (PBS; 0.2% Tween 20; 5% non-fat dry milk) and 
probed with the respective antibodies. For IDO protein detection a rabbit anti-mouse IDO 
polyclonal antibody (diluted 1:2500 in 1x PBST with 0.1% Tween, 5% BSA, 0.1% NaN3, 4°C 
O.N.) was kindly provided by O. Takikawa (National Institute for Longevity Sciences, 
National Center for Geriatrics and Gerontology, Japan) [147, 148] and a mouse monoclonal 
anti-mouse glyceraldehyde-3-phosphate dehydrogenase (GapdH) antibody (diluted 1:4000 in 
1x PBST with 0.1% Tween, 5% BSA, 0.1% NaN3, 1h RT) was purchased from Ambion 
(Austin, TX, USA) and used as an internal control. Detection of antibody binding was 
performed using the Odyssey Infrared Imaging System (Odyssey Classic; LI-COR 
Biosciences, Lincoln, Nebraska USA) according to the manufacturer’s instructions and the 
respective fluorescent secondary antibodies: Goat Anti-Rabbit IgG, DyLightTM800 
Conjugated and Goat Anti-Mouse IgG, DyLightTM680 Conjugated (Pierce Biotechnology/ 
Thermo Fisher Scientific, Rockford, IL., USA; diluted 1:20.000 in LI-COR blocking buffer; 
20min RT in the dark). 
 
4.4.4 RNA isolation and semiquantitative reverse transcription PCR 
 
Expression levels of IDO transcript in DCs were determined by semiquantitative reverse 
transcription-PCR procedure (RT-PCR). Total cellular RNA was isolated from cell 
populations and RT-PCR was performed by reverse transcription of 2µg total RNA. In brief, 
total RNA was isolated from cells with the use of TRIZOL reagent (Invitrogen) according to 
the recommendations of the manufacturer and stored at -80°C or immediately used for cDNA 
synthesis. RNA was reversed transcribed with 200 Units Moloney-murine leukemia virus (M-
MLV) reverse transcriptase (Invitrogen) and 100 pmol random hexamers (GE Healthcare, 
Vienna, Austria) at 42°C for 1 h. RT-PCR was performed using Hot Start Taq polymerase 
(Qiagen, Vienna, Austria) according to the manufacturer’s instructions with an initial 
activation step at 95°C for 14 min. Cycling conditions were as follows: denaturation at 95°C 
for 30 sec, annealing at 60°C for 30 sec, and elongation at 72°C for 1 min carried out for 35 
cycles, followed by a final extension at 72°C for 7 min. Amplification of the house keeping 
gene GapdH was used as internal PCR control. Oligonucleotides (MWG Biotech AG, 
Ebersberg, Germany) used for amplification of the murine IDO or of the murine GapdH and 
PCR product sizes are listed in Table 1. Amplification products were size-fractionated by 
agarose gel electrophoresis on a 1% agarose gel, stained with ethidium bromide and 
quantified by scanning densitometry (Gel-Doc 1000, Molecular Analyst Software, Biorad). 
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Gene                        Sense primer                                             Antisense primer                        Amplicon size(bp) 
 
IDO               CGA CAT AGC TAC CAG TCT GGA GAA AG         GCG AGG TGG AAC TTT CTC ACA GAG                     441 
 
GapdH         ACC ACA GTC CAT GCC ATC AC                             TCC ACC ACC CTG TTG CTG TA                                 452 
 
Table 1  Oligonucleotides and PCR product sizes for the determination of IDO and 
control gene expression 
 
4.4.5 Quantification of kynurenine, tryptophan and nitric oxide 
 
IDO enzymatic activity was determined by measuring the levels of tryptophan and kynurenine 
in the cell culture supernatants by high-pressure liquid chromatography (HPLC) as previously 
described [86, 149, 150] in cooperation with D. Fuchs (Institute of Medical Chemistry and 
Biochemistry, University of Innsbruck, Austria). Briefly, tryptophan was detected by its 
natural fluorescence at 286 nm excitation and 366 nm emission wavelengths. 3-Nitro-L-
tyrosine, used as an internal standard, and kynurenine were determined by ultraviolet 
absorption at 360 nm. An albumin-based external standard mix was prepared and included 50 
µM tryptophan (Serva, Heidelberg, Germany), 10 µM kynurenine (Sigma-Aldrich), and a 
frozen serum pool. Upon the addition of 25 µL of 2 M trichloroacetic acid  (Merck, 
Darmstadt, Germany) the reaction vials were immediately vortexed and centrifuged at 12 
000g (13 000 rpm) for 6 min at RT to precipitate protein. The concentration of the 
components was calculated according to peak heights and was compared with 3-nitro-L-
tyrosine as a reference standard. 
The production of nitric oxide (NO) in murine DCs produced by active iNOS (inducible nitric 
oxide synthase) into the cellular microenvironment was indirectly evaluated by measuring 
levels of nitrate and nitrite in the cell culture supernatants. The iNOS activity was determined 
in cooperation with D. Fuchs (Institute of Medical Chemistry and Biochemistry, University of 
Innsbruck, Austria) as previously described (Maloney, E. M., O. St Claire Morgan, et al. 
(2000). Briefly, concentrations of total nitrite and nitrate in cell supernatants were measured 
by Griess reaction: 75 µl A.d. and 125 µl Griess reagent were added to 50 µl of samples and 
the mixture was incubated for 10 min at RT. A 96-well-reader/photometer was used for 
determination of the absorption at 560 nm. 
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4.5 In vivo experiments 
 
4.5.1 Procedure of HSCT and adoptive T cell transfer 
 
Recipient C57BL/6 mice (female, 8-10 weeks old) received myeloablative irradiation therapy 
(10.0 Gy) as a conditioning regimen. A conventional source of x-ray irradiation was used 
(250 kV, tube 20x20 cm, 3.1 mm copper-, 0.8 mm tin-, 0.25 mm chromium- and 1.02 mm 
aluminum filter) at a dose rate of 0.5 Gy per minute. This type of irradiation has been 
routinely used for similar procedure [151] at the Department for Radiation Therapy, Medical 
University Vienna, Austria. Donor bone marrow cells (BMCs) were obtained from femora 
and tibiae of age-matched (6- to 10 week old) Balb/c donor mice as described above (chapter 
1.3.2.;Generation of BMDCs). Approximately 1 x 107 unseparated BMCs were infused into 
the tail vein of C57BL/6 recipients within 24 hours of myeloablation (d0, i.v.). This procedure 
generally allowed for rapid and uncomplicated engraftment. The Balb/c to BL/6 donor-
recipient strain combination is one of the most stringent models as it crosses MHC 
mismatches plus minor histocompatibility antigen mismatches [152].  
For the induction of GvHD in recipient C57BL/6 mice different tested concentrations (5 x 106 
or 1 x 107) of CD3+ T cells isolated of Balb/c donor derived total splenocytes as described 
above (chapter 4.3.4.; CD3+ T cell isolation) were adoptively transferred to HSCT recipients 
within 24 hours of myeloablation (d0, i.v.). 
 
4.5.2 GvHD monitoring 
 
The monitoring of the animals for GvHD included (i) daily scoring of clinical GvHD for ~ 
25-40 days according to the commonly used scoring system for murine bone marrow 
transplantation (BMT), (see below) (ii) the monitoring of the extent of chimerism (iii) the 
histopathological evaluation of autopsy material for the presence of GvHD in target organs.  
 
GvHD scoring  
The survival and appearance of mice were monitored daily and body weight was measured 
weekly. GvHD scoring included the assessment of the criteria as previously described [153] 
and illustrated in Table 2.  
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Table 2 Assessment of clinical GvHD in transplanted animals (Cooke et al.; Blood 
1996) 
 
Assessment of chimerism 
Blood was taken from the tail vein of recipient C57/BL6 mice following heating of the 
animals. The amount of blood taken did not exceed 1% of the body weight of the animals 
(~0.1-0.2 mL). Multilineage chimerism in a representative BMT recipient was analyzed by 
flow cytometry. CD4+ and CD8+ T cells, B cells (anti-B220) and myeloid cells were assessed 
for recipient chimerism in regular intervals by flow cytometry using the appropriate strain 
specific anti-HLA antibodies as described previously [151]. All antibodies used for chimerism 
studies are listed in chapter 4.4.1. Flow cytometry. 
 
Histopathological analysis of tissue samples 
At the end of the observation period HSCT recipients were sacrificed by cervical dislocation. 
Spleen, liver, gut, skin and lymphnode samples were examined by histopathology for typical 
signs of GvHD in collaboration with Fritz Wrba (Medical University of Vienna) in a blinded 
fashion. Four micrometers sections were cut from paraffin-embedded tissue fixed in 4.5% 
formalin (with a buffer pH of 7.5). Sections were stained with hematoxillin-eosin and Giesma 
according to standard protocols and were analyzed by an experienced pathologist. 
 
4.6 Statistical analysis 
 
All statistical analyses were performed using the Student t test (paired, 2-tailed). A P value 
below 0.05 was considered to indicate statistical significance. Survival curves were analyzed 
using the Kaplan-Meier algorithm.  
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5 Results 
 
5.1 Impact of CTLA-4Ig and IFN-γ on tryptophan catabolism in murine 
 splenic DCs 
 
Murine splenic DCs have been reported to express IDO protein and tryptophan metabolizing 
activity upon exposure to CTLA-4Ig and were reported to suppress allogeneic T cell 
responses in an IDO dependent manner [74, 154]. These finding led to the assumption that 
binding of CTLA-4Ig to CD80/86 of the DC can initiate, via “reverse” signaling, the 
upregulation of functional IDO leading to tryptophan catabolism that is sufficient to inhibit 
proliferative allogeneic T cell responses [75]. Similarly, IFN-γ was found capable to induce 
strong IDO protein expression in splenic DCs where IDO metabolic activity appeared to be 
restricted to the CD8α+ subset [69, 155]. However, some other studies showed that the 
immunmodulatory effect of CTLA-4Ig was independent of IDO activity [156, 157]. 
To pin down the effect of CTLA-4Ig on the induction of a DC regulatory phenotype through 
IDO in allogeneic stimulation, we treated splenic CD11c+ DCs with two different types of 
CTLA-4Ig fusion proteins (CTLA-4Ig (S); abatacept) or IFN-γ for 24h. Subsequently, the 
phenotype and capacity to acquire IDO expression and tryptophan metabolizing enzymatic 
activity were examined in these stimulated DCs.  
Highly enriched splenic CD11c+ DCs displayed a mature phenotype, indicated by the 
presence of MHC class I and MHC class II molecules, and high levels of expression of the co-
stimulatory molecules CD80 and CD86 [158, 159]. The exposure of DCs to CTLA-4Ig 
resulted in reduced detectability of CD80/CD86 co-stimulatory molecules as previously 
reported [75], suggesting that the fusion protein bound properly. However, abatacept affected 
particularly the CD80 molecule while leaving expression levels of CD86 largely unchanged. 
This finding is consistent with previous observations as CTLA-4Ig, binding both CD80 and 
CD86 but with a lower affinity to the latter one, was reported being less potent in inhibiting 
CD86- than CD80-dependent co-stimulation [135, 136]. Consistent with the specificity of 
CTLA-4Ig, no effect was observed on the expression levels of MHC class I and MHC class II 
molecules. No effect on CD80/CD86 expression was observed upon stimulation with IFN-γ 
(Figure 8). 
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Figure 8  Phenotypical analysis of splenic CD11c+ DCs. 
DCs were stimulated with two different types of CTLA-4Ig fusion proteins (CTLA-4Ig(S), 
abatacept) or IFN-γ for 24h and DC phenotype was analyzed by FACS. Expression levels of 
cell-surface molecules (MHCI, MHCII, CD80/CD86) typically associated with DC 
maturation are depicted (shaded histograms indicate isotype control; open black histograms, 
DCs after stimulation; open grey histograms, untreated DCs). One representative of 3 similar 
experiments is shown. 
 
Subsequently, splenic DCs were analyzed for expression of IDO-specific transcript by RT-
PCR. Consistent with previous reports [154], in the absence of CTLA-4Ig or IFN-γ, 
considerable expression of IDO mRNA was observed in splenic DCs in contrast to Baf3 cells, 
used as a negative control. However, this baseline level of IDO mRNA transcript was not 
upregulated upon stimulation with either CTLA-4Ig (CTLA-4Ig(S) and abatacept) or with 
IFN-γ (Figure 9A). Additionally, IDO expression was investigated by immunoblot analysis. 
In line with other studies, baseline levels of IDO protein were detected in freshly isolated 
splenic DCs even in the absence of a stimulus [75, 76, 154]. IDO expression in human IDO 
competent DCs [85] was used as positive control and purified T-lymphocytes served as a 
negative control. Similar to IDO mRNA expression, we did not find an increase of basal IDO 
protein expression levels upon stimulation with either CTLA-4Ig nor by stimulation with 
IFN-γ (Figure 9B). The failure of CTLA-4Ig and IFN-γ to enhance IDO transcription and 
expression above baseline level was confirmed by analysis of IDO enzymatic activity 
measured as tryptophan degradation and accumulation of kynurenine in the cell culture 
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supernatant. Neither CTLA-4Ig (CTLA-4Ig (S) and abatacept) nor IFN- γ caused a decrease 
of tryptophan levels and no increase of kynurenine levels was detectable in the cell culture 
supernatant at the termination of the activation period. The concentrations of kynurenine in 
untreated control cultures and in stimulated conditions consistently remained < 1 µmol/L 
(Figure 9C) in contrast to human DCs stimulated by a combination of LPS/IFN-γ [85]. Even 
excess doses of CTLA-4Ig up to 100 µg/mL or IFN-γ up to 3500 U/mL did not induce DCs to 
metabolize tryptophan (Table 3).  
 
 
Figure 9 IDO expression and enzymatic activity is not induced in CTLA-4Ig or IFN-γ 
stimulated splenic CD11c+ DCs.  
(A) IDO mRNA expression was analyzed by RT-PCR using total RNA from untreated, CTLA-
4Ig or IFN-γ treated DCs. Total RNA of murine Baf3 cells was used as negative control and 
GapdH as internal standard; NTC (non template control) indicates that no cDNA was added 
to the amplification mix during RT-PCR. (B) IDO protein expression in the same DCs as in 
(A) analyzed by immunoblotting. Human DCs stimulated by LPS/IFN-γ for 48h (human 
IDO+) as described [85] were used as positive and murine CD3+ T cells were used as 
negative controls. GapdH served as internal standard. (C) The concentrations of tryptophan 
(TRP; black bars, left scale) and kynurenine (KYN; grey bars, right scale) in cell culture 
supernatants of the same DCs as in (A) were determined by HPLC. Error bars indicate the 
range of a total of 6 consecutive experiments. 
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Table 3 Tryptophan (TRP) and kynurenine (KYN) concentrations measured by 
HPLC in cell culture supernatants of CD11c+ splenic DCs stimulated for 24h with increasing 
concentrations  (0-100 µg/mL) CTLA-4Ig (abatacept) or IFN-γ (0-3500 U/mL). 
 
Due to the fact that exposure of splenic CD11c+ DCs to CTLA-4Ig or IFN-γ did not induce 
enzymatic activity of IDO, we next investigated whether IDO activity would be inhibited in 
those stimulated DCs. One possible mechanism for inhibition of IDO enzymatic activity is the 
accumulation of NO, produced by the IDO antagonist iNOS, into the cellular 
microenvironment of DCs [72]. Thus DCs were stimulated with two different types of CTLA-
4Ig fusion proteins or IFN-γ for 24h as described above and iNOS enzymatic activity was 
analyzed by measuring NO concentrations in the cell culture supernatants. However, no 
significant increase of NO levels was detectable in the cell culture supernatants of both, 
CTLA-4Ig or IFN-γ stimulated DCs at the termination of the activation period. NO levels 
measured by HPLC in untreated control cultures and in stimulated conditions consistently 
remained <1 µmol/L (Figure 10). Hence, iNOS activity is not induced in splenic DCs upon 
stimulation with CTLA-4Ig or IFN-γ and is not involved in the incapability of these 
stimulated DCs to acquire functional IDO activity. 
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Figure 10 iNOS enzymatic activity is not induced in stimulated splenic CD11c+ DCs.  
DCs were stimulated for 24h with CTLA-4Ig (CTLA-4Ig(S); abatacept) or IFN-γ and the 
concentrations of nitric oxide (NO; black bars) in cell culture supernatants were determined 
by HPLC. Error bars indicate the range of a total of 6 consecutive experiments. 
 
In a separate set of experiments, we specifically enriched total splenic CD11c+ DCs for their 
minute (~5%) CD8α+ population and examined whether this particular DC subpopulation 
acquired IDO competence through CTLA-4Ig or IFN-γ as reported previously [154, 160]. 
However, like the total splenic DCs, the CD8α+ DCs, while displaying baseline levels of IDO 
protein expression, did not acquire the capability to metabolize tryptophan and produce 
kynurenines upon stimulation with CTLA-4Ig or IFN-γ. The concentrations of kynurenine in 
untreated control cultures and in stimulated conditions consistently remained < 1 µmol/L 
(Table 4). 
 
 
Table 4  Tryptophan (TRP) and kynurenine (KYN) concentrations measured by  
HPLC in cell culture supernatants of CD8α+ splenic DCs stimulated for 24h with 40 µg/mL 
CTLA-4Ig (CTLA-4Ig(S); abatacept) or 200 U/mL IFN-γ. Results of 1 experiment, 
representative of 2 experiments, are shown.  
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Finally, we examined whether CTLA-4Ig exposure in vivo would induce IDO enzymatic 
activity in splenic DCs as previously reported [74, 75]. Therefore, 100µg of CTLA-4Ig(S) or 
isotype-matched purified IgG2a were injected intraperitoneally (i.p.) into C57BL/6 mice. 
Splenic CD11c+ DCs were recovered 24h after treatment of mice with CTLA-4Ig or purified 
IgG2a and IDO enzymatic activity was analyzed in cell culture supernatants. Anyhow, even 
CTLA-4Ig exposure in vivo did not induce functional IDO activity in splenic DCs. 
Kynurenine concentrations consistently remained < 1 µmol/L in both, supernatants of DCs 
recovered from CTLA-4Ig(S) or IgG2a treated mice (Figure 11). 
 
 
Figure 11  CTLA-4Ig exposure in vivo to induce IDO enzymatic activity in splenic DCs. 
C57BL/6 mice received 100µg CTLA-4Ig (S) or isotype-matched purified IgG2a (i.p.). Splenic 
CD11c+ DCs were isolated 24h after treatment of mice with CTLA-4Ig or IgG2a and cultured 
in IMDM complete medium until the next day. Tryptophan (TRP; black bars, left scale) and 
kynurenine (KYN; grey bars, right scale) concentrations in cell culture supernatants were 
determined by HPLC. Error bars indicate the range of a total of 3 consecutive experiments. 
 
Taken together, these findings suggest that in the present study neither CTLA-4Ig nor IFN-γ 
were able to induce IDO expression or enzymatic activity in splenic C57BL/6 DCs. 
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5.2 CTLA-4Ig primes splenic DCs for IFN-γ production but fails to 
 initiate IDO competence 
 
Since we could not detect any IDO activity in splenic DCs upon stimulation with CTLA-4Ig 
fusion proteins, we decided to verify whether CTLA-4Ig would have an effect on DCs at all. 
Therefore, we next sought to test whether CTLA-4Ig had an effect on DC IFN-γ production, 
as CTLA4-Ig binding to co-stimulatory molecules CD80/CD86 was reported to elicit IFN-γ 
production by DCs finally inducing IDO activity in an autocrine and/ or paracrine fashion [71, 
76]. 
Thus, we measured IFN-γ release in the supernatants of CTLA-4Ig (abatacept; CTLA-4Ig(S)) 
treated versus untreated DCs. In these experiments we found that the exposure of DCs to both 
types of CTLA-4Ig fusion proteins caused a slight increase of IFN-γ secretion by C57BL/6 
splenic DCs (Figure 12A). However this increase did not result in detectable tryptophan 
consumption or kynurenine production (Figure 12B).  
 
 
Figure 12 Induction of IFN-γ release in C57BL/6 splenic CD11c+ DCs by CTLA-4Ig. 
(A) The amount of IFN-γ release in cell culture supernatants of splenic DCs treated with 
CTLA-4Ig (CTLA-4Ig(S); abatacept) for 24 h was analyzed by ELISA technique. The asterisk 
indicates significant differences between CTLA-4Ig treated and untreated DCs (*P < 0.05). 
Error bars indicate the range of a total of 3 consecutive experiments. (B) Cell culture 
supernatants of DCs stimulated as in (A) were analyzed for IDO activity by HPLC at the end 
of the 24h stimulation period in parallel. Tryptophan (TRP; black bars, left scale) and 
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kynurenine (KYN; grey bars, right scale) concentrations in µmol/L are depicted. Error bars 
indicate the range of a total of 3 consecutive experiments.  
 
Similar findings were obtained with splenic CD11c+ DCs obtained from DBA/2J mice [76] 
(Figure 13). These findings finally excluded that the lack of IDO induction in DCs, exposed 
to CTLA-4Ig, was limited to the C57BL/6 strain. 
 
 
Figure 13 The effect of CTLA-4Ig on splenic CD11c+ DCs obtained from DBA/2J mice. 
(A) Splenic DCs were exposed to CTLA-4Ig (S) for 24h and IDO protein expression was 
examined by immunoblot analysis. (B) Concentrations of tryptophan (TRP; black bars, left 
scale) and kynurenine (KYN; grey bars, right scale) were examined by HPLC in cell culture 
supernatants of the same DCs as in (A). (C) Cell culture supernatants of the same DCs as in 
(A) were examined for IFN-γ release by ELISA technique. Results of 1 experiment, 
representative of 2 experiments, are shown.  
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In summary, the two types of CTLA-4Ig fusion proteins tested caused DCs to produce IFN-γ 
but consistently failed to induce DCs to acquire IDO expression and activity. 
 
5.3 Exposure of splenic DCs to CTLA-4Ig or IFN-γ does not confer a DC 
 regulatory phenotype 
 
From the recently reported effect of CTLA-4Ig on DCs it was assumed that CTLA-4Ig 
conferred a regulatory DC phenotype [75]. To explicitly address whether CTLA-4Ig or IFN-γ 
affect the stimulatory capacity of DCs per se, we devised an experiment, in which the DC 
population was pre-exposed to CTLA-4Ig or IFN-γ and washed before stimulating allogeneic 
T cells. Like in the experiments above, C57BL/6 splenic DCs were exposed to the different 
types of CTLA-4Ig fusion proteins (abatacept; CTLA-4Ig(S)) or IFN-γ for 24 hours or left 
untreated. At the end of the 24-hour pre-stimulation period the DCs were thoroughly washed 
and co-cultured with Balb/c T cells (mixed lymphocyte reaction, MLR) and the amount of 
allogeneic T cell responses was determined by CFSE dilution.  
C57BL/6 derived splenic DCs were identified as potent stimulators of allogeneic Balb/c T 
cells, resulting in a proportion of approximately ~ 70% (71 ± 1.9%, mean ± SEM, n=3) of 
CFSE- T cells after a 6 day co-culture period (Figure 14). Strikingly, a pre-exposure of these 
DCs to CTLA-4Ig or IFN-γ did not reduce the capacity of the DCs to subsequently stimulate 
allogeneic T cells. In fact, C57BL/6 DCs induced comparable allogeneic T cell proliferation 
irrespective of whether they were left untreated or pre-exposed to CTLA-4Ig (abatacept; 
CTLA-4Ig(S)) or IFN-γ (Figure 14). This experimental outcome indicated that DCs pre-
exposed to CTLA-4Ig or IFN-γ did not acquire a regulatory phenotype in vitro.  
 
 
Figure 14 CTLA-4Ig and IFN-γ do not induce a DC regulatory phenotype. 
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C57BL/6 splenic CD11c+ DCs were stimulated with CTLA-4Ig fusion proteins (abatacept; 
CTLA-4Ig) or IFN-γ for 24h. Thereafter, cells were thoroughly washed and co-cultured with 
Balb/c CD3+ T cells. T cell proliferative responses were determined at the end of the culture 
period (day 6) by CFSE dilution and are depicted as per cent CFSE negative cells. Results of 
one experiment, representative of 3 experiments, are shown. 
 
5.4 LPS/IFN-γ matured BMDCs fail to acquire IDO competence and to 
 dampen allogeneic T cell responses in co-cultures 
 
Recently, our group demonstrated that human monocyte-derived DCs acquire sustained IDO 
competence upon activation with a combination of LPS and IFN-γ for 48h and that these IDO 
competent DCs downregulated allogeneic T cell responses in vitro [85]. Furthermore, in an in 
vitro study that investigated murine BMDCs in the context of IDO mediated 
immunosuppression, IDO expression was found to be upregulated in BMDCs upon exposure 
to LPS or IFN-γ [161].   
Thus, we activated C57BL/6 bone marrow derived immature DCs (iDCs) with LPS in the 
presence or absence of IFN-γ for 48h and examined the phenotype and their capacity to 
acquire IDO competence. iDCs displayed very low expression levels of MHC class I /II 
molecules and of the co-stimulatory molecules CD80/CD86. DC activation with LPS alone or 
in combination with IFN-γ (LPS/IFN-γ) for 48h resulted in the upregulation of the surface 
markers MHC class I/II and CD80/CD86 in comparison to iDCs and DCs cultured for 48h 
without maturation stimuli (unstimulated) (Figure 15A). Next, BMDCs were analyzed for 
constitutive IDO transcription by RT-PCR. Some basal level of expression of IDO mRNA 
was detected in iDCs and 48-hour untreated DCs. As reported previously in Jung et.al. 2007 
[161], this baseline level of IDO mRNA expression was slightly upregulated upon exposing 
DCs to LPS or LPS/IFN-γ for 48h (Figure 15B). Similarly, the baseline levels of IDO protein 
expression detectable by immunoblot analysis were slightly enhanced after exposing the DCs 
to LPS or LPS/IFN-γ (Figure 15C). However, BMDCs did not acquire tryptophan 
metabolizing activity upon stimulation with LPS/IFN-γ. The concentrations of kynurenine 
measured by HPLC in the supernatants of iDCs, untreated and stimulated BMDCs remained < 
1 µmol/L contrary to human DCs stimulated by a combination with LPS/IFN-γ (Figure 15D). 
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Figure 15 IDO expression and enzymatic activity is not induced in C57BL/6 BMDCs 
upon exposure to LPS/IFN-γ. 
(A) Phenotype of immature BMDCs (iDCs) and LPS or LPS/IFN-γ matured (48h) BMDCs 
analyzed by flow cytometry. Expression levels of cell-surface molecules (MHCI, MHCII, 
CD80/CD86) typically associated with DC maturation are illustrated (black bars; median 
peak channel). One representative of 3 similar experiments is shown. (B) IDO mRNA 
expression of the same DCs as in (A) as analyzed by RT-PCR. Total RNA of murine Baf3 cells 
was used as negative control and GapdH as internal standard; NTC, non template control. 
(C) IDO protein expression in the same DCs as in (A) analyzed by immunoblotting. Human 
DCs stimulated by LPS/IFN-γ for 48h (human IDO+) or 4h (human IDO-) as described [85] 
were used as positive and negative controls. GapdH served as internal standard. (D) 
Concentrations of tryptophan (TRP; black bars, left scale) and kynurenine (KYN; grey bars, 
right scale ) in cell culture supernatants of the same DCs as in (A) as determined by HPLC. 
Error bars indicate the range of a total of 6 consecutive experiments. 
 
To examine, whether LPS/IFN-γ matured BMDCs confer a DC regulatory capacity, DCs were 
pre-exposed to LPS/IFN-γ before a co-culture with allogeneic T cells. Briefly, C57BL/6 iDCs 
were stimulated with LPS or by combination with LPS/IFN-γ for 48h or left untreated. At the 
end of the 48-hour stimulation period DCs were thoroughly washed and co-cultured with 
Balb/c derived T cells. The capacity to stimulate allogeneic T cell responses was determined 
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by CFSE dilution at the end of the culture period. C57BL/6 BMDCs were potent stimulators 
of allogeneic Balb/c T cells, resulting in ~ 65% (64.7 ± 2.2%, n=3) CFSE- T cells after a 6 day 
co-culture (Figure 16). However, a pre-exposure of these DCs to LPS/IFN-γ did not reduce 
the stimulatory capacity of the DCs. In fact, both LPS and LPS/IFN-γ stimulated BMDCs 
rather boosted allogeneic T cell responses as compared to untreated BMDCs (Figure 16). 
Together, 48-hour matured BMDCs did not acquire functional IDO activity and were not able 
to dampen allogeneic T cell responses in vitro. 
 
 
Figure 16 C57BL/6 BMDCs exposed to LPS/IFN-γ for 48h do not dampen allogeneic T 
cell responses. 
C57BL/6 BMDCs were stimulated with LPS in the presence or absence with IFN-γ for 48h. 
Subsequently, cells were thoroughly washed and co-cultured with Balb/c CD3+ T cells. T cell 
proliferative responses were determined by CFSE dilution after 6 days and are expressed as 
per cent CFSE negative cells. Results of one experiment, representative of 3 experiments, are 
shown. 
 
5.5 CTLA-4Ig directly affects the interaction of stimulator and responder 
 cells in co-cultures 
 
CTLA-4Ig was reported to potently inhibit allogeneic T cell proliferation when added at the 
time at which DCs interacted with allogeneic T cells, suggesting that CTLA-4Ig directly 
prevented the activation of the co-stimulatory pathway signals [145]. This observation is in 
line with the original concept of CTLA-4Ig to block the interaction of CD80/CD86 with their 
counter-receptor CD28. 
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When CTLA-4Ig was added at the initiation of the DC/ T cell co-culture (C57BL/6 splenic 
DCs were used as stimulators of Balb/c CD3+ T cells) and was present during the MLR, we 
found, as expected, a significant reduction of allogeneic T cell proliferative responses. CTLA-
4Ig being present throughout the MLR inhibited T cell proliferation in a dose dependent 
manner with 100 µg/mL resulting in an inhibition of proliferation of 68% ± 0,5% (mean ± 
SEM) by day 3 of the MLR [145], in three consecutive experiments (P<0.001) (Figure 17). Of 
note, similar effects of CTLA-4Ig were observed when BMDCs were used as stimulators of 
allogeneic T cells (see below Figure 21).  
 
 
Figure 17 CTLA-4Ig impairs the interaction of stimulator and responder cells in MLRs. 
C57BL/6 splenic DCs were stimulated with CTLA-4Ig fusion proteins (abatacept; CTLA-4Ig)  
or IFN-γ for 24h. At the end of the stimulation period, DCs were thoroughly washed and co- 
cultured with Balb/c CD3+ T cells. CTLA-4Ig (abatacept; 100µg/mL) was added to the co-
cultures at day 0 and thus was present for the total period of the MLR (right panel) or co-
cultures were left untreated (left panel). T cell proliferative responses were analyzed by CFSE 
dilution after 3 days and are depicted as per cent CFSE negative cells or as the per cent 
divided cells (see Materials and Methods). Results of 1 experiment, representative of 3 
experiments, are shown (P < 0.01). 
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To exclude that CTLA-4Ig would reduce T cell responses independently of binding to co-
stimulatory molecules on DCs, we performed DC independent T cell proliferation assays. For 
this purpose, we stimulated CD3+ T cells using plate bound anti-CD3/ anti-CD28 in the 
presence or absence of increasing concentrations of CTLA-4Ig. In these experiments, CTLA-
4Ig did not reduce T cell proliferation, even in excess concentrations, (Figure 18A) and had 
no toxic effect on T cells (Figure 18B).  
 
 
Figure 18 CTLA-4Ig does not affect per se the proliferative capacity of T cells. 
(A) Purified Balb/c CD3+ T cell were stimulated with plate bound anti-CD3/ anti-CD28 for 
48h in the presence or absence of increasing concentrations (0-200µg/mL) of CTLA-4Ig 
(abatacept; CTLA-4Ig (S)). T cell proliferation was assessed by CFSE dilution. (B) CD3+ T 
cells of (A) were analyzed for per cent of living (DAPI negative) cells. Results of 1 
experiment, representative of 2 experiments, are shown. 
 
Together, our findings strongly suggest that the immunmodulatory agent CTLA-4Ig neither 
promotes regulatory activity in DCs nor affects per se the proliferative capacity of T cells but 
directly interferes with the interaction of stimulator and responder cells in DC/ T cell co-
cultures. 
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5.6 The immunmodulatory effect of CTLA-4Ig preferentially affects the 
 CD4+ T cell response and preserves a CD4+CD25high phenotype 
 
Next, in order to examine the effect of CTLA-4Ig on the major T cell subsets in allogeneic 
responses, MLRs were performed in the presence or absence of CTLA-4Ig (abatacept) as 
described above. After 3 days of co-culture proliferative responses were examined separately 
in CD4+ and CD8+ T cell populations by CFSE dilution.  
As expected, both CD4+ and CD8+ T cells underwent considerable cell division by ~ 50% 
when stimulated with allogeneic DCs in the absence of CTLA-4Ig (Figure 19, black bars). In 
contrast and consistent with previous results [136, 162] we found that particularly CD4+ T 
cells were inhibited to proliferate when CTLA-4Ig was present throughout the co-cultures (79 
± 0.5%, mean inhibition ± SEM), whereas the proliferation of CD8+ T cells was largely spared 
form the effect (9 ± 1%, mean inhibition ± SEM) (Figure 19, grey bars).  
 
 
Figure 19 CTLA-4Ig preferentially affects the CD4+ T cell population in an MLR. 
MLRs were performed with untreated splenic DCs and allogeneic Balb/c CD3+ T cells in the 
presence or absence CTLA-4Ig (abatacept). After 3 days of co-culture the percent viable 
CD3+CD25+ T cells (left panel) were separated into CD4+CD25+ (upper right) and 
CD8+CD25+ (lower right) T cell populations by flow cytometry and individually examined for 
CFSE dilution. **Significant (P < 0.001) differences of CTLA-4Ig treated and untreated co-
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cultures; n.s. indicates not significant. Error bars indicate the range of a total of 3 
consecutive experiments. 
 
Additionally, we found that at the end of the culture period by day 6 a proportion of CD4+ T 
cells with a CD25 high phenotype was preserved in those co-cultures performed in the 
presence of CTLA-4Ig (abatacept; CTLA-4Ig(S)) in contrast to co-cultures in the absence of 
CTLA-4Ig. This CD4+CD25high preserved T cell population represented 40% of all living 
CD4+CD25+ T cells (Figure 20). 
 
 
Figure 20 In an MLR, CTLA-4Ig preserves a CD4+CD25high phenotype. 
Proliferative responses of CD4+ T lymphocytes in response to allogeneic splenic DCs, which 
were left untreated, in the presence or absence of CTLA-4 Ig (abatacept or CTLA-4Ig (S) 
were analyzed by CFSE dilution. At the end of the culture period (day 6) cells were gated for 
viable CD4+ T cells. The proportion of CD4+CD25highCFSE-negative T cells of total 
CD4+CD25+CFSE-negative T cells is depicted (black boxes). Results are from 1 of 3 
representative experiments (P < 0.05). 
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Thus, our findings suggest that CTLA-4Ig, preferentially affecting the CD4+ T cell response 
when present during co-cultures, preserves a CD4+CD25high putatively regulatory phenotype.  
 
5.7 The presence of CTLA-4Ig during co-cultures propagates T cells 
 displaying a CD4+CD25+FoxP3+ phenotype 
 
T cell expression of the CD25 molecule may indicate cellular activation or regulatory cells 
[163]. To distinguish whether the CD4+CD25+ T cell population induced by CTLA-4Ig 
represents regulatory cells, we next examined the T cells having undergone allogeneic 
stimulation in the presence of CTLA-4Ig for expression of the key molecules associated with 
murine regulatory T cells, FoxP3 and CD62L [164, 165]. 
In this set of experiments, BMDCs were generated from C57BL/6 mice and were used as 
stimulators of allogeneic Balb/c CD3+ T cells in the presence or absence of CTLA-4Ig 
(abatacept). The allogeneic T cell response, determined by CFSE dilution, was inhibited by 
50% in co-cultures where CTLA-4Ig was present throughout the MLR as compared to co-
cultures that were left untreated (Figure 21A).  
For characterization of a regulatory phenotype, T cells of the differently treated co-cultures 
were recovered and analyzed by flow cytometry. As a positive control we used CD4+CD25+ 
naturally occurring regulatory T cells (nTregs) isolated from lymph nodes of Balb/c mice 
which usually represent 5-10% of total CD4+ T cells and have been reported to constitutively 
express FoxP3. As depicted in Figure 21B (upper row) nTregs showed high expression levels 
of the surface markers CD25 and CD62L and as well highly expressed intracellular FoxP3. 
Similar to these nTregs, the CD4+CD25+ T cell population having been exposed to CTLA-4Ig 
during the MLR highly expressed intracellular FoxP3 and the surface marker CD62L, 
suggesting a regulatory phenotype. In contrast, in CD4+CD25+ T cells recovered from the 
MLR in which CTLA-4Ig was absent during the co-culture, the proportion of cells expressing 
CD62L and intracellular Foxp3 was low (Figure 21B).  
 
Hence, CTLA-4Ig, in addition to quantitatively down-regulating the allogeneic proliferative 
CD4+ T cell response when present in a MLR, supported the development of regulatory T 
cells. 
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Figure 21 CD4+CD25+ T cells recovered from an MLR performed in the presence of 
CTLA-4Ig harbor a regulatory phenotype. 
(A) C57BL/6 BMDCs were used as stimulators of Balb/c derived CD3+ T cells in the absence 
or presence of CTLA-4Ig (abatacept). Proliferative responses of CD4+ T cells were analyzed 
by CFSE dilution at the end of the co-culture period. (B) MLRs performed as in (A) but 
without staining T cells with CFSE were harvested and the CD4+CD25+ T cell population 
from co-cultures in the absence or presence of CTLA-4Ig was examined for the expression of 
the key cellular markers indicating a regulatory phenotype, intracellular FoxP3 and cell 
surface CD62L. Dotted grey lines indicate isotype controls. Balb/c CD4+CD25+ cells isolated 
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from lymph nodes and representing naturally occurring regulatory T cells (nTregs) were used 
as positive control. Results of one experiment, representative of 2 experiments are shown. 
 
5.8 The effect of CTLA-4Ig on allogeneic CD4+ T cells is sustained upon 
 restimulation 
 
Co-stimulation blockade by CTLA-4Ig has been associated with the induction of sustained T 
cell unresponsiveness [166]. 
To test whether the effect of CTLA-4Ig to dampen allogeneic CD4+ T cell responses was 
sustained or transient, a second round MLR was performed. Briefly, CD3+ T cells of the first 
MLR, performed in the presence or absence of CTLA-4Ig, were harvested, stained with CFSE 
and restimulated in a subsequent MLR (2nd round MLR) with the same stimulator cells but in 
the absence of CTLA-4Ig. Both, CD4+ and CD8+ cell populations having undergone 
stimulation by allogeneic DCs in the absence of CTLA-4Ig showed a rapid proliferative 
response upon restimulation (Figure 22A, upper panel). However, when the first MLR was 
performed in the presence of CTLA-4Ig, CD4+ T cells were still inhibited to mount a full 
proliferative response in 2nd round MLR. Particularly, the per cent divided cells as calculated 
by the FlowJo program (see Materials and Methods chapter 4.3.5) was reduced by 50% (per 
cent divided cells 44.8% in cells derived from MLR in the absence of CTLA-4Ig versus 
22.5% in cells being derived from MLRs performed in the presence of CTLA-4Ig). Similar to 
the findings in the first MLR, the CD8+ T cell population was less affected by CTLA-4Ig, the 
per cent divided cells in the 2nd round MLR being 55.5% and 42.6% whether the first MLR 
was performed in the absence or the presence of CTLA-4Ig, respectively (Figure 23A, lower 
panel). Remarkably, in addition to the quantitative reduction of proliferation, the expression 
levels of CD25 and FoxP3 were retained in CD4+ T cells upon restimulation when the first 
MLR was performed in the presence of CTLA-4Ig. In contrast, CD4+ T cells having 
undergone allogeneic stimulation in the absence of CTLA-4Ig revealed a CD25 low FoxP3 
low phenotype (Figure 22B). 
 
Together, we here demonstrate that the inhibitory effect of CTLA-4Ig on allogeneic 
stimulation is sustained in the CD4+ T cell population and that a T cell regulatory phenotype 
is preserved upon restimulation. 
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Figure 22 The effect of CTLA-4Ig on CD4+ allo responses is preserved in a second 
round MLR. 
(A) T cells were recovered from first MLRs which were performed with BMDCs as 
stimulators of Balb/c derived CD3+ T cells in the presence or absence of CTLA-4Ig 
(abatacept). Thereafter, recovered cells were washed, stained with CFSE and were 
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restimulated with the same allo-antigens (freshly generated C57BL/6 BMDCs) but in the 
absence of CTLA-4Ig (2nd round MLR). Proliferative responses to 2nd stimulation were 
analyzed by CFSE dilution, including the determination of the per cent divided cells (see 
inserted numbers) using FlowJo proliferation platform. (B) T cells of the 2nd round MLR from 
(A) were recovered and CD4+ T cells were examined for intracellular expression of FoxP3. 
Dotted grey lines indicate isotype controls. Balb/c CD4+CD25+ nTregs isolated from lymph 
nodes were used as a positive control. Results of one experiment, representative of 2 
experiments are shown. 
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5.9 Establishment of an in vivo HSCT/ GvHD model 
 
5.9.1 Preliminary data and future perspectives 
 
As mentioned before, in HSCT, T cells play a central role in immune reconstitution but have 
the potential to induce GvHD [54]. Thus, a very important task of research in the field of 
HSCT is to support the allo-HSCT recipient with T cells which are tolerant against recipient 
allo-antigens to protect the recipient from GvHD while maintaining T cell immunity against 
pathogens. One possible approach is to generate such T cells ex vivo and use these T cells for 
adoptive transfer strategies.  
In our murine model of HSCT, we hypothesize that those donor T cells of allo MLRs, which 
were exposed to CTLA-4Ig, will protect recipient mice from developing GvHD when 
adoptively transferred in the recipient strain. In contrast to this, T cells of the allo MLRs 
performed in the absence of CTLA-4Ig are supposed to induce GvHD in the recipient strain 
after adoptive transfer.  
Therefore, we first established an in vivo HSCT/ GvHD mouse model to study whether the 
hypothetically tolerized T cells are able to protect recipients from GvHD. Briefly, for murine 
allogeneic HSCT, host conditioning for successful BMC engraftment was mediated by 
myeloablative irradiation (10 Gy) of recipient C57BL/6 mice one day prior to BMT. 
Subsequently within 24h, mice were transplanted with a conventional dose of approximately 
10 x 106 Balb/c donor derived BMCs.  
This procedure allowed for rapid and uncomplicated engraftment. Lineage-specific chimerism 
of transplanted animals was determined by flow cytometry of peripheral white blood cells 
which were stained with the appropriate donor strain-specific anti-HLA antibody and specific 
cell lineage markers. Three weeks after transplantation donor BMCs successfully engrafted in 
6 out of 6 recipient C57BL/6 mice as depicted in Figure 23.  
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Figure 23 Lineage specific chimerism in a representative C57BL/6 bone marrow 
transplantation (BMT) recipient. 
Flow cytometric analyses of peripheral white blood cells of (A) Balb/c mice and (B) BMT 
recipient C57BL/6 mice stained with the appropriate donor strain-specific anti HLA antibody 
(H-2Dd) and specific cell lineage markers against CD4+ and CD8+ T cells, B cells (ant-B220) 
and myeloid cells (anti-MAC1) three weeks after BMT. One representative example out of 6 
Balb/c and C57BL/6 BMT recipients is depicted. 
 
To define the appropriate donor T cell amount to successfully induce GvHD in C57BL/6 
recipient mice, we followed protocols published by Cohen et.al. 2002 [46]. In brief, CD3+ T 
cells were isolated of total splenocytes derived from donor Balb/c mice as described above. 
Thereafter, these donor T cells (10 x 106 or 5 x 106) were adoptively transferred together with 
10 x 106 donor derived BMCs to C57BL/6 HSCT recipients (2 groups of 6 mice) within 24h 
of myeloablation via the tail vein. Additionally, to confirm successful engraftment one group 
of C57BL/6 recipients received donor derived BMCs (10 x 106) without donor T cells. The 
survival and appearance of recipient mice were monitored daily and assessed according to a 
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GvHD scoring procedure previously described by Cooke et. al.1996 [153] and body weight 
was determined weekly.  
C57BL/6 recipient mice transplanted with BMCs and 5 x 106 T cells derived from Balb/c 
donors developed classical signs characteristic of clinical GvHD from ~ day 14 post 
transplantation (p.t.) onwards and died within 30 days p.t. (Figure 24; red line). These signs 
included (i) weight loss (15-25%) (Figure 25, red bars), (ii) kyphotic posture leading to 
impaired movement and reduced activity, (iii) moderate to severe ruffled, poor groomed and 
scaly fur texture and (iv) declined skin integrity (scaling of paws, ears and around eyes) 
indicating a grade 2 GvHD (Figure 25). GvHD was further confirmed by histopathology (not 
shown). C57BL/6 mice transplanted with Balb/c derived BMCs and an overdose of 10 x 106 T 
cells died very rapidly within 2 weeks p.t. without developing the above mentioned typical 
signs for GvHD except for weight loss (Figure 24, green line; Figure 25 green bars). C57BL/6 
mice of the control group transplanted with donor derived BMCs survived more than 35 days 
and developed no signs related to GvHD (Figure 24, blue line; Figure 25, blue bars). 
 
 
Figure 24 Survival curves after HSCT and allogeneic T cell transfer. 
C57BL/6 recipient mice received a myeloablative irradiation dose of 10 Gy one day prior to 
bone marrow transplantation (BMT). Within 24 hours after lethal irradiation, 10 x 106 bone 
marrow cells (BMCs) (group 1; blue line), 10 x 106 BMCs + 5 x 106 CD3+ T cells (group 2; 
red line) or 10 x 106 BMCs + 10 x 106 CD3+ T cells (group 3; green line) were injected into 
recipients (n=6 per group) via the tail vein. The survival of recipients was monitored daily. 
Survival curves were analyzed using the Kaplan-Meier algorithm. On representative out of 2 
consecutive experiments is shown. 
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Figure 25 Assessment of GvHD in C57BL/6 recipient mice. 
(A) C57BL/6 recipient mice were lethally irradiated (10 Gy), separated into 3 groups (n=6) 
and received 10 x 106 Balb/c donor derived bone marrow cells (BMCs) (group 1) in 
combination with 5 x 106 (group 2) or 10 x 106 (group 3) CD3+ T cells from Balb/c donors by 
tail vein injection. The body weight of recipients was determined weekly. (B) Appearance of 
recipient mice from (A) was monitored daily and evaluated according to a GvHD index as 
describe in Cooke et. al.1996 [153]. (n=2). 
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To summarize, we successfully established an in vivo HSCT/ GvHD mouse model. First, we 
defined the minimal myeloablative irradiation dose and the rescuing cell dose of donor 
BMCs. Second, we defined the optimal donor T cell amount to induce GvHD in C57BL/6 
recipients followed by a successful evaluation of grade 2 GvHD in transplanted animals. 
Further experiments to directly test the tolerogenic capacity of the hypothetically tolerized T 
cells of allo MLRs performed in the presence of CTLA-4Ig are in progress. 
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6 Summary and Discussion 
 
In the mammalian immune system T cells are inclined to recognize and initiate immune 
responses towards allo-antigens. Therefore, a key task in transplantation research, including 
both solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT), is 
to develop approaches to achieve a state of allo-specific tolerance. Allo-specific tolerance 
implies that T cells do not mount pathogenic immune reaction towards the allogeneic organ 
but preserve their protective activity towards environmental pathogens. Thus, the generation 
of allo-specific tolerized T cells may be critical to improve transplantation outcomes as to 
overcome the detrimental effects of pathogenic immune reactions in host-versus-graft and 
graft-versus-host direction prevailing in SOD and HSCT, respectively. 
In numerous previous studies co-stimulation blockade has been shown to represent an 
effective means of generation of anergic T cells. 
The major contribution of the present study to advance the understanding of the cellular 
mechanisms of CTLA-4Ig mediated inhibition of allogeneic T cell responses is by showing 
that CTLA-4Ig (i) does not require IDO activity, nor leads to the induction of a DC regulatory 
phenotype, but (ii) acts through directly impairing DC/T cell interaction and (iii) affects CD4+ 
T cell responses not only quantitatively but also qualitatively by fostering the emergence of 
regulatory T cells.  
CTLA-4Ig has been originally developed based on the concept that specific binding to CD80 
and CD86 molecules expressed on APCs interrupts CD28 mediated stimulatory signaling in T 
cells [135, 167]. CD28 mediated signaling stimulates key pathways indispensible for an 
efficacious T cell response, such as cell proliferation, increased cell survival and a marked 
increase of cytokine secretion directing T cell differentiation towards a Th1 phenotype. In 
contrast, a blockade of this pathway has been linked to the emergence of anergy, with low IL-
2 production and enhanced T cell death involving both passive cell death and activation 
induced cell death as underlying mechanisms [168]. These effects of CTLA-4Ig resulting 
from blocking the CD28:CD80/86 pathway have been solidly evidenced in numerous in vitro 
and in vivo studies [96, 166, 167, 169].  
In 2002, Grohmann et al. [75] proposed a novel concept for the mechanism of CTLA-4Ig 
mediating tolerance. In their model, CTLA-4Ig binding to CD80/CD86 molecules would not 
only inhibit CD80/86 interaction with CD28 but provide a ‘reverse’ signal to DCs resulting in 
the production of IFN-γ and the induction of IDO [170]. IDO is the major and rate limiting 
enzyme of tryptophan metabolism in the mammalian organism apart from the liver [60]. It 
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metabolizes tryptophan along the kynurenine pathway. The resulting tryptophan depletion and 
kynurenine accumulation in the intercellular microenvironment interfere with the T cell 
proliferative capacity and promote apoptotic decline. Thus, IDO activity in DCs, has been 
shown to possess powerful immune regulatory and tolerance inducing capacity [171].  The 
concept of Grohmann et al. led to the assumption that binding of CTLA-4Ig to CD80/86 of 
the DC inducing tryptophan catabolism is critical to mediate the tolerogenic capacity of 
CTLA-4Ig [130]. The induction of IDO activity by CTLA-4Ig was therefore proposed to 
induce a regulatory DC phenotype. The model proposed by Grohmann et al. was confirmed 
by another study, where specific subsets of splenic DCs were identified to mediate potent 
IDO-dependent T cell suppression in vitro following CTLA-4Ig exposure in vivo [74]. Yet, in 
their experimental system CTLA-4Ig-mediated IDO upregulation or IDO-dependent T cell 
suppression did not require IFN-γ signals as demonstrated by the use of IFN-γ-receptor 
deficient mice. The reason for the different role of IFN-γ in IDO upregulation remained 
unsolved. The authors assumed that differences in experimental approaches, including mouse 
stain-specific factors could be a possible explanation for such disparities [74]. However, the 
role of CTLA-4Ig in inducing IDO activity in allogeneic stimulation has since been 
controversially discussed. Pree et al. showed that CTLA-4Ig, while being essential for the 
development of mixed chimerism in a murine model of non-myeloablative BMT, did not 
involve tryptophan metabolism and its effect was not reversed by the IDO inhibitor 1-methyl 
tryptophan (1-MT) [156]. In another study, CTLA-4Ig expressed in a murine DC cell line 
promoted tolerogenesis without inducing IDO expression [172]. Likewise, Davis and 
coworkers showed that abatacept did not induce IDO mRNA and kynurenine production in 
human monocyte-derived DCs [157]. 
IFN-γ is considered as one of the most prominent IDO inducers, which increases the 
transcriptional activity of the IDO promoter region via effects on signal transducer and 
activator of transcription (STAT1) and interferon regulatory factor 1 (IRF-1) [173, 174]. IDO 
induction mediated by IFN-γ signaling was reported to be involved in human [65, 66] and 
murine DCs [82, 154, 155]. The control of IDO transcription is complex and IDO activity is 
as well tightly regulated at the posttranslational level and thus, IDO protein can be expressed 
without functional activity as reviewed in Mellor et al. 2004  [171]. IFN-γ was found capable 
to induce strong IDO expression in murine splenic CD11c+ DCs, yet, IDO metabolic activity 
seemed to be preferentially limited to the CD8α+ subset [81, 82, 175]. Anyhow, it was 
reported that IFN-γ treatment of both CD8α+ and CD8α- splenic DC subsets resulted in 
comparable upregulation of IDO mRNA and protein expression [154]. Another study showed 
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that it was also possible to induce IDO enzymatic activity and a DC regulatory phenotype in 
CD11c+ splenic DCs without separation into CD8a+ and CD8a- subsets [75].  
The present study comprehensively addressed the issue of IDO induction through CTLA-4Ig 
or IFN-γ, including the use of different mouse strains, different CTLA-4Ig fusion protein 
preparations, and broad assessment of IDO expression on mRNA and on protein level and 
enzymatic activity, ultimately seeking for CTLA-4Ig or IFN-γ mediated tolerance induction 
via IDO. However, the composite findings unequivocally showed that CTLA-4Ig 
immunoregulatory activity occurred in an IDO independent fashion. In effect, while we 
confirmed previous findings of CTLA-4Ig inducing C57BL/6 derived DCs to produce IFN-
[76] CTLA-4Ig did not induce the IDO pathway in splenic murine DCs. DCs which were 
pre-exposed to CTLA-4Ig before being used to stimulate allogeneic T cells retained their 
ability to subsequently fully stimulate T cell responses. This observation might be explained 
by the rapid dissociation rate of CTLA-4Ig from CD80 and CD86 [134]. Yet, it clearly argues 
against the view that CTLA-4Ig induces a DC regulatory phenotype. Similarly, IDO 
expression and enzymatic activity was not induced in splenic DCs upon stimulation with IFN-
γ. In addition, a pre-exposure of splenic DCs to IFN-γ did not confer a DC regulatory 
phenotype in vitro.  
Recently a human study demonstrated that monocyte-derived DCs acquire sustained IDO 
competence upon activation with a combination of LPS and IFN-γ for 48h and that these IDO 
competent DCs downregulated allogeneic T cell responses in vitro [85]. However, in the 
murine system, only little information is available about IDO activity in BMDCs. In 2007, 
Jung et al. suggested that IDO expression in murine C57BL/6 BMDCs could be either 
induced upon stimulation with LPS or IFN-γ. Their findings indicated that LPS-induced IDO 
expression was controlled by an IFN-γ independent pathway and was mediated by PI3K and 
JNK. In contrast, induction of IDO expression by IFN-γ stimulation was reported to be 
dependent on JAK signaling [161]. At this point, one has to keep in mind that IDO protein 
expression in DCs does not necessarily mean that IDO is enzymatic active as reviewed in 
Mellor et al. 2003 [176]. In line with the findings of Jung et al. we found increased IDO 
mRNA and protein expression levels when C57BL/6 BMDCs were stimulated with LPS or in 
combination with LPS/IFN-γ. However, in contrast to the human system where IDO activity 
was routinely measured in terms of tryptophan degradation and kynurenine accumulation in 
the supernatant of 48h-LPS/IFN-γ matured DCs, murine BMDCs did not acquire functional 
IDO activity and were not able to dampen allogeneic T cell responses in vitro.  
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One possibility for the lack of IDO activity in murine DCs upon exposure to either CTLA-4Ig 
or IFN-γ or LPS in combination with IFN-γ that came into our mind was the inhibition of 
IDO activity by the IDO antagonist iNOS. It was reported that NO produced by iNOS inhibits 
IDO activity [72]. Interactions between tryptophan depletion and NO production were first 
described in studies by Thomas et al. demonstrating that IDO activity in IFN-γ primed human 
mononuclear phagocytes was inhibited by chemical NO donors [177]. Another study revealed 
that NO negatively modulated transcription of the IDO gene in mouse macrophages [178]. 
Further, IDO protein expression and enzymatic activity in extracts of IFN-γ stimulated rat 
cells were found to be inhibited by endogenous and exogenous NO, while transcription of 
Indo, the gene coding for IDO, was not affected [80]. Further studies accomplished by the 
same group revealed that IDO is degraded by NO in the proteasome [80]. In the present study, 
we did not find enhanced NO levels measured in the supernatants of the differently stimulated 
DCs. Therefore our results indicate that iNOS activity was not involved in the incapability of 
the stimulated DCs to acquire functional IDO activity. 
The definitive explanation of the discrepant findings in the diverse studies addressing an 
association of CTLA-4Ig or IFN-γ and IDO induction remains unsolved at this point. As 
previously debated, seemingly trivial differences in experimental procedures [85, 179, 180] or 
CTLA-4Ig preparations (e.g., in the original study by Grohmann et al. CTLA-4Ig was fused to 
an IgG3 subclass [75]) may underlie the discrepancies. Irrespectively, the present findings 
strongly indicate that the immunomodulatory effect of CTLA-4Ig is not strictly dependent of 
the IDO pathway. 
 
In fact, CTLA-4Ig was, as expected from previous reports [145], able to potently inhibit 
allogeneic T cell proliferation when added at the time at which DCs interacted with allogeneic 
T cells. This suggests that CTLA-4Ig directly prevented the activation of the co-stimulatory 
pathway signals, which is in line with the original concept of CTLA-4Ig via blocking the 
interaction of CD80/86 with their counterpart CD28.  
As well consistent with previous reports, we found the CD4+ T cell population to be more 
affected as compared to the CD8+ T cell population [162, 181]. In addition to inhibiting CD4+ 
cell proliferation quantitatively, CTLA-4Ig present during DC/T cell co-cultures also 
promoted the CD4+CD25+ T cell population to display a regulatory FoxP3+CD62L+ 
phenotype. FoxP3 expression in mice is viewed as the master transcription factor controlling 
development and function of Tregs [164, 182, 183]. In the murine system, CD4+CD25– T 
cells when stimulated in vitro do not express FoxP3 [164, 182] contrary to the observations 
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made in the human system [85, 184, 185]. Thus, the stable FoxP3 expression of the CD4+ T 
cell population as propagated by CTLA-4Ig which is retained upon a second stimulation 
indicates the emergence of bona fide regulatory T cells.  
The role of Tregs cells in the context of CTLA-4Ig mediated co-stimulation blockade is 
puzzling. In principle, the homeostasis of Tregs has been proposed to be dependent on CD28 
signaling. Therefore, CTLA-4Ig as it blocks CD28 mediated signal transduction has been 
suspected to negatively interfere with Treg survival and to even lead to exacerbation of 
autoimmune diseases [186]. Furthermore, CTLA-4Ig by its binding to CD80/86 may also 
affect the interaction of CD80/86 with CTLA-4, thus preventing the transmission of the 
counterstimulatory signals to T cells [135]. Contrary to this hypothetical view, some reports 
suggested that CTLA-4Ig leads to an augmentation of Tregs [187], possibly by a conversion 
of CD4+CD25– cells to CD4+CD25+ T regulatory cells [188]. Others reported CTLA-4Ig 
treated DCs to acquire the ability to prevent collagen-induced arthritis and this efficacy of 
CTLA-4Ig was associated with an increase of CD4+CD25+FoxP3+ cells. This DCs’ ability 
occurred without involving IDO, and suggested a role for CTLA-4Ig rendering DCs able to 
enhance the emergence of Treg cells [189]. Co-stimulation blockade, in contrast, failed to 
enlarge the CD4+CD25+FOXP3+ Treg population in a human study of patients having 
received kidney transplantation, [190], pointing at the previously recognized profound 
difference of CTLA-4Ig in human and rodent models [133, 191]. In the long term, however, 
CTLA-4Ig did not negatively interfere with Treg survival [192].  Finally, a specific role for 
CD4+ Treg cells for tolerizing the CD8+ T cell population was proposed [167].  
While published reports preclude a definitive conclusion, the finding of this study, i.e. CTLA-
4Ig propagating Tregs, warrant further testing. The generation of Treg populations through 
CTLA-4Ig ex-vivo might be beneficial for adoptive transfer strategies after transplantation to 
ameliorate pathogenic alloreactivity in the host-versus-graft as well as in the graft-versus-host 
direction. Such an approach is currently extensively studied in our laboratory. 
 
In summary, the findings of this study support the view that of co-stimulation blockade by 
CTLA-4Ig effects potent immunoregulatory activity in an IDO independent fashion. By direct 
interference with the interaction of APCs and T cells, CTLA-4 affects predominantly the 
CD4+ T cell population through two cellular mechanisms, inhibition of proliferation and 
allowing the emergence of a CD4+ T cell population harbouring a regulatory phenotype.  
 
71 
7 Manuscript 
 
CTLA-4Ig propagating CD4+CD25+FoxP3+ regulatory T cells in an indoleamine 2,3-
dioxygenase independent fashion 
 
Edda Veith (1), Nina Pilat (2), Dietmar Fuchs (3), Thomas Wekerle (2), Andreas Heitger (1) 
 
(1) Children’s Cancer Research Institute, Division Transplantation Immunology, Vienna, 
Austria 
(2) Division of Transplantation, Department of Surgery, Medical University Vienna, Austria 
(3) Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Austria 
 
Running title 
CTLA-4Ig promoting Tregs independent of IDO 
 
Key words: CTLA-4Ig, abatacept, IFN-, IDO, Treg  
 
Corresponding author 
Andreas Heitger, M.D. 
Children's Cancer Research Institute 
Zimmermannplatz 10 
A – 1090 Vienna, Austria 
Phone:  +43 1 40 470 4070 
FAX:  +43 1 470 64070 
E-mail: andreas.heitger@ccri.at 
 
Final draft; submitted 
 
72 
Abstract 
Immunosuppressive CTLA-4Ig fusion proteins block the CD28:CD80/86 costimulatory 
pathway but have also been reported to affect DC function via the induction of the 
immunosuppressive indoleamine 2,3 dioxygenase (IDO) pathway, thus promoting a DC 
regulatory phenotype. We here probed immunoregulation by CTLA-4Ig isotypes, including 
abatacept, in an allogeneic setting using C57BL/6 derived splenic and bone marrow derived 
DCs as stimulators of allogeneic Balb/c derived T cells. CTLA4-Ig potently dampened 
allogeneic T cell responses when present during T cell/DC co-culture. Although slightly 
inducing DC IFN-γ secretion, the dampening effect was neither related to activating the IDO 
pathway nor to the induction of a DC regulatory phenotype. Instead, CTLA-4Ig appeared to 
directly interrupt the DC/T cell crosstalk, preferentially affecting the CD4+ T cell population. 
Moreover, CD4+CD25+ T cells recovered from DC/T cell co-cultures performed in the 
presence of CTLA4-Ig displayed CD62L+ FoxP3+ expression, compatible with a regulatory 
phenotype. Remarkably, this regulatory phenotype was preserved upon restimulation. In 
conclusion, CTLA-Ig affected allo-stimulated T cell responses quantitatively and qualitatively 
but independently of IDO. Expanding T regulatory cells as propagated by CTLA-4Ig may 
possess therapeutic potential.  
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Introduction 
A major task in transplantation research, including solid organ transplantation (SOT) and 
hematopoietic stem cell transplantation (HSCT), is to achieve a state of allo-specific 
tolerance.  T cells play a key role in the regulating transplantation immunology. Allo-specific 
T cell tolerance implies that T cells do not mount pathogenic immune reactions towards 
allogeneic organs but preserve protective activity towards environmental pathogens. Thus, the 
generation of allo-specific tolerized T cells may be critical to improve transplantation 
outcomes. 
 T cells in order to mount appropriate responses upon antigen recognition need to 
receive costimulatory signals. Costimulatory signaling involves a multitude of costimulatory 
molecules present on APCs interacting with their appropriate receptors on T cells to finally 
optimize T cell proliferation and cytokine secretion (reviewed in [193]). Previous studies have 
shown that antigen stimulation of T cells in the absence of costimulation will leave T cells 
anergic, i.e. unresponsive to subsequent stimulation by the same antigen [166, 167, 191]. The 
most extensively studied costimulatory pathway required for the induction of full T cell 
immune responses is the interaction of CD80 and CD86 molecules expressed on DCs with the 
CD28 molecule expressed on T cells. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is 
expressed by activated T cells and mediates a T cell inhibitory signal thus counteracting 
CD28-mediated signaling to limit excess T cell stimulation. CTLA-4 has a much higher 
binding affinity to CD80 and CD86 molecules than CD28. CTLA-4 immunoglobulin fusion 
proteins (CTLA-4Ig) have been pharmacologically engineered to block CD28-mediated 
costimulatory signaling to T cells and thus to induce tolerance [194]. CTLA-4Ig consists of 
the extracellular binding domain of CTLA-4 linked to an Fc domain of IgG and possesses a 
high binding affinity to CD80 and CD86, (reviewed in [126, 135]). 
 In 2002, Grohmann et al. [75] proposed a novel mechanistic concept for CTLA-4Ig 
mediating immunosuppression. In their model, CTLA-4Ig binding to CD80/CD86 molecules 
would provide a ‘reverse’ signal to DCs resulting in the production of IFN-γ and the induction 
of indoleamine 2,3 dioxygenase (IDO) [170]. IDO is the major and rate limiting enzyme of 
tryptophan metabolism in mammals initiating tryptophan metabolism along the kynurenine 
pathway [60]. The resulting tryptophan depletion and kynurenine accumulation in the 
intercellular microenvironment interfere with the T cell proliferative capacity and promote T 
cell apoptotic decline. Thus, IDO activity in DCs has been proposed to possess powerful 
immune regulatory and tolerance inducing capacity [171]. The concept of Grohmann et al. led 
to the assumption that binding of CTLA-4Ig to CD80/86 induces a regulatory DC phenotype 
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in an IDO dependent manner. This mechanism was proposed to critically underlie the 
tolerogenic capacity of CTLA-4Ig [130].  
In the present study, our findings, unexpectedly, provide solid evidence that 
immunoregulation by CTLA-4Ig does neither require IDO activity nor the induction of a DC 
regulatory phenotype; CTLA-4Ig, instead, mediated regulation of allogeneic T cell 
proliferation by directly interfering with DC/T cell interaction and supported the emergence 
of CD4+ T regulatory cells. 
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Materials and Methods 
Mice and reagents 
Female C57BL/6 (H-2b), DBA/2J (H-2d), and Balb/c (H-2d) mice, aged six to 10 weeks 
(Charles River Laboratories, Sulzfeld, Germany) were maintained under specific pathogen-
free conditions at the Biomedical Research Institute, Medical University of Vienna (Austria). 
All experiments were approved by the institutional review board and followed the national 
and international guidelines of laboratory animal care.  
Human CTLA-4Ig fusion protein (IgG1) (abatacept) [129, 157] was generously provided by 
Bristol-Meyers Squibb Pharmaceuticals (Princeton, NJ, USA). Recombinant mouse cytolytic 
CTLA-4Ig (IgG2a), termed CTLA-4Ig (S), was purchased from Sigma (Sigma Aldrich, St. 
Louis, MO, USA). Interferon-gamma (IFN-γ) cytokine secretion was examined using the BD 
OptEIA mouse IFN-γ ELISA set (BD Biosciences, San Diego, CA, USA).  
 
Cell culture medium 
All assays were performed in IMDM (Invitrogen, Carlsbad, USA) containing 2 mM L-
glutamin and 25 mM Hepes supplemented with 10% FBS (PAA Laboratories, Austria), 
antibiotics and 50 µM 2-mercaptoethanol (Sigma), hereafter termed complete medium. Cell 
cultures were maintained in humidified air containing 5% CO2 at 37°C. 
 
Cell preparation 
Splenic DCs were enriched from C57BL/6 mice following previously described protocols [74, 
75] and personal recommendations (F. Fallarino, Perugia, Italy).  
In brief, spleens were injected with collagenase (type IV, Sigma, 100U/ml) and placed in 
collagenase IV (400U/ml) solution for 30min at 37°C and made into single cells suspensions. 
Single cells were recovered in 50% isoosmotic Nycodenz solution (Sigma), and centrifuged at 
450g. The low density fraction was adhered for 2h and non-adherent cells were removed. 
After further 18h, the detached cells were recovered. Alternatively, DCs were enriched by 
magnetic cell sorting (MACS) using CD11c selection columns (Miltenyi Biotec, Bergisch-
Gladbach, Germany). The DC phenotype was examined by assessing the expression of 
CD11c, CD11b, MHC class I and II, CD80 and CD86. Either procedure yielded ~90% 
CD11c+ cells which contained ~90-95% CD8α– and 5-10% CD8α+ cells. CD8α+ 
subpopulations were enriched by ≥90% using the CD8+ DC isolation kit (Miltenyi Biotec). 
BM derived DCs (BMDCs) were generated from mouse BM as previously described [144]. 
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Immature BMDCs expressed CD11c and CD11b (> 80%) and low levels of MHC class I/II 
and CD80/CD86. 
For DC activation, splenic DCs (1x106/mL per well) were plated in 24-well culture plates 
(IWAKI) and exposed to CTLA-4Ig (40µg/ml) [75] for 24h. BMDCs were activated by 
100ng/mL LPS (E. coli O111:B4, Calbiochem, San Diego, CA) and IFN-γ (200U/ml, BD 
Biosciences) for 48h, which induced high levels of MHC class I/II and CD80/86 expression. 
T cells were enriched from Balb/c spleens using the Pan T Cell Isolation Kit (MACS; 
Miltenyi Biotec, routinely yielding >95% CD3+ cells. 
 
T cell stimulation and mixed lymphocyte reaction (MLR) 
CD3+ T cells (1x105) were co-cultured with allogeneic DCs (1x104) for 3 to 6 d in 96-well 
round bottom plates (NUNC; Thermo Fisher) in triplicates in 200µL complete medium per 
well (MLR). For DC independent T cell proliferation assays, CD3+ T cells (1x105) were 
stimulated with 3µg/mL immobilized anti-CD3 and 1µg/mL anti-CD28 (BD Biosciences) for 
48h.  
T cell proliferation was assessed by CFSE (Sigma) dilution as previously described [146]. 
Where indicated, the FlowJo Proliferation Platform (Tree Star, Ashland, OR, USA) was used 
to calculate the per cent divided cells. These are defined as the total per cent of cells of the 
starting population that divided (assuming that no cells died during the culture) irrespective of 
the number of cell divisions. Inhibition of proliferation was calculated as follows: Per cent 
inhibition = [1- (per cent CFSE– T cells in co-cultures with CTLA-4Ig/per cent CFSE– T cells 
in co-cultures without CTLA-4Ig)] x 100. 
 
Flow cytometry  
Flow cytometric examinations were performed using a FACSCalibur or a BD LSR II flow 
cytometer (BD Biosciences). List mode data were analyzed using either DivaCell (BD 
Biosciences) or FlowJo (Tree Star) software. The following Abs were used: unconjugated 
anti-CD16/32 (2.4G2), FITC-anti-H-2D[b] (KH95), PE-anti-I-A[b] (AF6-120.1), PE-Cy7-
anti-CD11c (HL3), APC-Cy7-anti-CD11b (M1/70), PerCP-anti-CD8a (53-6.7), APC-anti-
CD3 (145-2C11), PerCP-anti-CD4 (RM4-5), APC-Cy7-anti-CD8a (53-6.7), PE-Cy7-anti-
CD25 (PC61) (all from BD Biosciences), PerCP/Cy5.5-anti-CD80 (16-10A1), Alexa Fluor 
700-anti-CD86 (PO3), FITC-anti-CD62L (MEL14), APC-anti-CD90.2 (30-H12) (all from 
BioLegend). The Alexa Fluor 647 anti-mouse/rat/human FOXP3 Flow Kit (BioLegend, San 
Diego, CA, USA) was used for detection of FoxP3 expression in T cells,. 
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Immunoblotting 
IDO protein expression in DCs was investigated using a rabbit anti-mouse IDO polyclonal Ab 
kindly provided by O. Takikawa (National Institute for Longevity Sciences, National Center 
for Geriatrics and Gerontology, Japan) [147]. Mouse monoclonal anti-mouse GapdH Ab 
(Ambion, Austin, TX, USA) was used as an internal control. Ab binding was visualized using 
the Odyssey Infrared Imaging System (Odyssey Classic; LI-COR Biosciences, Lincoln, NE, 
USA) and the respective fluorescent secondary Abs: goat anti-rabbit IgG, DyLight800 
conjugated and goat anti-mouse IgG, DyLight680 conjugated (Pierce Biotechnology, 
Rockford, IL, USA). 
 
IDO mRNA detection  
Expression levels of IDO transcript in DCs were determined by semiquantitative RT-PCR. In 
brief, total RNA was isolated from cells with the use of trizol reagent (Invitrogen, Lofer, 
Austria). RNA was reversely transcribed with 200 Units Moloney-murine leukemia virus RT 
(Invitrogen) and 100pmol random hexamers (GE Healthcare, Vienna, Austria) at 42°C for 1h. 
RT-PCR was performed using Hot Start Taq polymerase (Qiagen, Vienna, Austria). 
Oligonucleotides (MWG Biotech AG, Ebersberg, Germany) used for amplification of the 
murine IDO or of the murine GapdH were as follows: IDO, 5’-CGACATAGCTACCA 
GTCTGGAGAAAG-3’ and 5’-GCGAGGTGGAACTTTCTCACAGAG-3’; GapdH, 5’-AC 
CACAGTCCATGCCATCAC-3’ and 5’-TCCACCACCCTGTTGCTGTA-3’. Amplification 
products were size-fractionated by agarose gel electrophoresis on a 1% agarose gel, stained 
with ethidium bromide and quantified by scanning densitometry (Gel-Doc 1000, Molecular 
Analyst Software, Biorad, Hercules, CA).  
 
Quantification of tryptophan and kynurenine 
IDO enzymatic activity was determined by measuring the levels of tryptophan and kynurenine 
in the cell culture supernatants by HPLC as described [85]. 
 
Statistical analysis 
All statistical analyses were performed with the Student t test (paired, 2-tailed). A P-value 
<0.05 was considered to indicate statistical significance. 
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Results 
 
CTLA-4Ig primes DCs for IFN-γ production but fails to initiate IDO competence  
To pin down the effect of CTLA-4Ig on the induction of a DC regulatory phenotype via IDO, 
we prepared C57BL/6 splenic CD11c+ DCs in the same manner as described [75, 195] and 
stimulated these DCs using two isotypes of CTLA-4Ig. Splenic CD11c+ DCs displayed a 
mature phenotype, indicated by MHC class I/II expression and by expression of high levels of 
the costimulatory molecules CD80 and CD86 [158, 159] (Figure 1A). CTLA-4Ig binding to 
CD80/CD86 reduced the detectability of these costimulatory molecules with the notion that 
abatacept affected particularly the CD80 molecule while leaving expression levels of CD86 
largely unchanged [134]. Consistent with the specificity of CTLA-4Ig, no effect was observed 
on the expression levels of MHC class I/II molecules. (Figure 1A).  
Next, C57BL/6 splenic DCs were analyzed for expression of IDO-specific transcript by RT-
PCR. Consistent with previous reports [154], some basal level of expression of IDO mRNA 
was detected in DCs even in the absence of CTLA-4Ig (Figure 1B), compatible with a 
constitutive expression of IDO. However, this baseline level of IDO mRNA expression was 
not increased after exposing the DCs to either CTLA-4Ig isotype (Figure 1B). Likewise, the 
baseline levels of IDO protein expression detectable by immunoblotting remained the same 
upon exposing DCs to CTLA-4Ig (Figure 1C). Finally, CTLA-4Ig did not induce IDO 
activity. Indeed, kynurenine production in both untreated control and CTLA-4Ig stimulated 
DCs consistently remained <1 µmol/L (Figure 1D). Even excess doses of CTLA-4Ig up to 
100µg/ml did not induce DC IDO activity (Supplementary Table 1). Thus, CTLA-4Ig failed 
to induce IDO expression or enzymatic activity in splenic C57BL/6 DCs. 
We next sought to test whether CTLA-4Ig had an effect on DC IFN-γ production, since 
CTLA-4Ig binding to costimulatory molecules was reported to elicit IFN-γ production by 
DCs finally inducing IDO activity [76, 77].  The exposure of DCs to both CTLA-4Ig isotypes 
caused a slight increase of IFN-γ secretion by C57BL/6 splenic DCs (Figure 2A). However, 
this increase did not result in tryptophan consumption or kynurenine production (Figure 2B). 
Similar findings were obtained with splenic DCs obtained from DBA/2J mice [76] 
(Supplementary Figure 1). These findings finally excluded that the lack of IDO by CTLA-4Ig 
induction was limited to the C57BL/6 strain.  
In a separate experiment, we specifically enriched C57BL/6 DCs for their minute (~5%) 
CD8α+ population and examined whether this particular DC subpopulation acquired IDO 
competence through CTLA-4Ig [154, 196]. However, like the total splenic DCs, the CD8α+ 
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cells, while displaying baseline levels of IDO protein, did not acquire the capability to 
metabolize tryptophan and produce kynurenines by CTLA-4Ig (Supplementary Table 2) 
In summary, the two isotypes of CTLA-4Ig tested caused DCs to produce IFN-γ but 
consistently failed to induce IDO expression and activity.   
 
CTLA-4Ig does not confer a DC regulatory phenotype but directly affects the 
interaction of stimulator and responder cells  
To explicitly address whether CTLA-4Ig induces a DC regulatory phenotype, we devised an 
experiment in which the DC population was pre-exposed to CTLA-4Ig before stimulating 
allogeneic T cells. C57BL/6 splenic DCs were exposed to CTLA-4Ig for 24 hours as above 
and thoroughly washed before being co-cultured with Balb/c T cells. Allogeneic T cell 
responses were quantified by CFSE dilution.  
C57BL/6 derived splenic DCs were potent stimulators of allogeneic Balb/c T cells, resulting 
in ~70% (71 ± 1.9%, mean ± SEM, n=3) CFSE– T cells after a 6 day co-culture (Fig 3A). 
Strikingly, a pre-exposure of these DCs to CTLA-4Ig did not reduce the stimulatory capacity 
of the DCs. In fact, C57BL/6 DCs induced comparable allogeneic T cell proliferation 
irrespective of whether they were left untreated or pre-exposed to CTLA-4Ig (Fig 3A).  
In contrast, when CTLA-4Ig was added at the initiation of the MLR and was present 
throughout the DC/T cell co-culture, we found, as expected, a significant inhibition of 
allogeneic T cell proliferative responses. CTLA-4Ig inhibited T cell proliferation in a dose 
dependent manner (not shown) with 100µg/ml resulting in an inhibition of proliferation of 
68%± 0.5% (mean ±SEM) by day 3 of the MLR [145], in three consecutive experiments 
(P<0.001) (Fig 3B). Of note, similar effects of CTLA-4Ig were observed when BMDCs were 
used as stimulators of allogeneic T cells (see below).  
To exclude that CTLA-4Ig reduces T cell responses independently of binding to 
costimulatory molecules on DCs, we performed DC independent T cell proliferation assays in 
the presence of increasing concentrations of CTLA-4Ig. In these experiments, CTLA-4Ig did 
not reduce T cell proliferation even at excess concentrations (Figure 3C) and did not have a 
toxic effect on T cells (not shown).  
Together, these findings indicate that CTLA-4Ig neither promotes regulatory activity in DCs 
nor affects per se the proliferative capacity of T cells but directly interferes with the 
interaction of stimulator and responder cells in DC/T cell co-cultures.  
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CTLA-4Ig preferentially affects the CD4+ T cell response and propagates T cells 
displaying a CD4+CD25+FoxP3+ phenotype 
Next, CFSE dilution was examined separately in CD4+ and CD8+ T cell populations. 
Consistent with previous results [136, 162], particularly the CD4+ T cells were inhibited to 
proliferate when CTLA-4Ig was present throughout the MLR (79±0.5%, mean inhibition 
±SEM), whereas the proliferation of CD8+ T cells was largely spared form the effect (9±1%, 
mean inhibition ± SEM) (Fig 4).  
 Since CD4+CD25+ T cell populations may represent activated or regulatory cells 
[163], we examined T cells recovered from MLRs performed in the presence of CTLA-4Ig for 
expression of the key molecules associated with murine Treg cells, FoxP3 and CD62L [164]. 
In this set of experiments, C57BL/6 BMDCs were used as stimulators of MLRs which were 
performed in the presence (abatacept) or absence of CTLA-4Ig. In the experiment depicted in 
Fig 5, the allogeneic T cell proliferation was inhibited by 50% (not shown). Strikingly, the 
CD4+CD25+ T cell population emerging from MLRs performed in the presence of CTLA-4 Ig 
largely (83.0%) displayed a FoxP3+CD62L+ phenotype.  In contrast, in CD4+CD25+ T cells 
recovered from MLRs in which CTLA-4Ig was absent the proportion of FoxP3+CD62L+ cells 
was low.  
Thus in allogeneic stimulation, CTLA-4Ig, in addition to quantitatively down-regulating 
proliferation of CD4+ T cells, supported the development of regulatory T cells. 
 
The effect of CTLA-4Ig on allogeneic CD4+ cells is preserved upon restimulation 
To test whether the effect of CTLA-4Ig dampening allogeneic CD4+ T cell responses was 
sustained, a second MLR was performed. Briefly, the CD3+ T cells of the first MLR, 
performed in the presence or absence of CTLA-4Ig, were harvested, stained with CFSE and 
restimulated in a second MLR with the same stimulator cells but in the absence of CTLA-4Ig. 
Both, CD4+ and CD8+ cell populations having been stimulated by allogeneic DCs in the 
absence of CTLA-4Ig showed a rapid proliferative response upon restimulation (Fig 6A, 
upper panel). However, when the first MLR was performed in the presence of CTLA-4Ig, the 
CD4+ cells remained significantly inhibited to mount a full proliferative response in a second 
MLR (Fig 6B). Particularly, the per cent divided cells as calculated by the FlowJo program 
was reduced by 50%. Like in the first MLR, the CD8+ population was less affected by CTLA-
4Ig, (24% inhibition, Fig 6B). Remarkably, in addition to the quantitative reduction of 
proliferation, the expression levels of CD25 and FoxP3 were retained in CD4+ T cells upon 
restimulation when the first MLR was performed in the presence of CTLA-4Ig. This was in 
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contrast to CD4+ T cells having undergone allogeneic stimulation in the absence of CTLA-4Ig 
(Fig 6B).  
Together, we here demonstrate that the inhibitory effect of CTLA-4Ig on allogeneic 
stimulation is sustained in the CD4+ T cell population and that a T cell regulatory phenotype 
is preserved upon restimulation. 
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Discussion 
The present study advances the understanding of the cellular mechanisms of immune 
regulation by CTLA-4Ig as follows: CTLA-4Ig immune inhibition (i) does not rely on IDO 
activity, and not on the induction of a DC regulatory phenotype, but (ii) acts through directly 
impairing DC/T cell interaction and (iii) affects CD4+ T cell responses not only quantitatively 
but also qualitatively by supporting the emergence of regulatory T cells.  
 CTLA-4Ig has been originally developed based on the concept that specific binding to 
CD80/CD86 molecules expressed on DCs interrupts CD28 mediated signalling to T cells 
(reviewed in [135, 167]) and thus can support the emergence of anergy [168]. This effect of 
CTLA-4Ig has been solidly evidenced in numerous in vitro and in vivo studies [96, 166, 169]. 
The recently reported new facet of the cellular mechanism of CTLA-4Ig claiming that CTLA-
4Ig binding to CD80/CD86 transmits a signal back to DCs to ultimately result in activation of 
the immunomodulatory IDO pathway [75, 196] laid the basis for conceptualizing 
immunoregulatory CTLA-4Ig to involve a DC regulatory phenotype in an IDO dependent 
fashion. This understanding has stimulated a controversial debate. Pree et al showed that 
CTLA-4Ig, while being essential for the development of mixed chimerism in a murine model 
of non-myeloablative BMT, did not involve tryptophan metabolism and its effect was not 
reversed by inhibition of IDO [156]. Several further murine and human studies reported that 
the tolerogenic effect of CTLA-4 Ig occurred without the involvement of IDO [157, 197].  
The present study comprehensively addressed the issue of IDO induction through CTLA-4Ig, 
including the use of different mouse strains, different CTLA-4Ig fusion protein preparations, 
and broad assessment of IDO expression on mRNA and on protein level and enzymatic 
activity, ultimately seeking for CTLA-4Ig mediated tolerance induction via IDO. However, 
the composite findings unequivocally demonstrated that CTLA-4Ig immunoregulatory 
activity occurred in an IDO independent fashion. In effect, while we confirmed previous 
findings of CTLA-4Ig inducing DCs to produce IFN-γ [76], CTLA-4Ig did not induce the 
IDO pathway. Moreover, CTLA-4Ig, when added to DC cultures and removed before using 
the DCs to stimulate allogeneic T cells, had no effect on subsequent allogeneic T cell 
responses. This finding might be related to the rapid dissociation rate of CTLA-4Ig from 
CD80 and CD86 [134]; yet, it clearly argues against the view that CTLA-4Ig induces a DC 
regulatory phenotype.  
 The problem of discrepant findings in the diverse studies addressing an association of 
CTLA-4Ig and IDO induction remains unsolved at this point. As previously debated, 
seemingly trivial differences in experimental procedures [85, 179, 180] or CTLA-4Ig 
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preparations (e.g., in the original study by Grohmann et al., CTLA-4 was fused to an IgG3 
subclass [75]) may underlie the discrepancies.  Irrespectively, the present findings strongly 
indicate that the immunomodulatory effect of CTLA-4Ig is not strictly dependent on the IDO 
pathway. In fact, CTLA-4Ig was, as expected from previous reports [145], able to potently 
inhibit allogeneic T cell proliferation when present at the time when DCs interacted with 
allogeneic T cells. This suggests that CTLA-4Ig directly interfered with costimulatory 
pathway signals, which is in keeping with the original concept of CTLA-4Ig.  
In additio to the previously reported preferential effect on CD4+ T cells [162, 181], we show 
that CTLA-4Ig promoted the CD4+CD25+ cell population to display a regulatory 
FoxP3+CD62L+ phenotype. FoxP3 expression in mice is viewed as the master transcription 
factor controlling development and function of Tregs [164, 182, 183]. In the murine system, T 
cells stimulated in vitro do not express FoxP3 (ibidem), contrary to the observations in the 
human system [85, 184, 185]. Thus, FoxP3 expression of the CD4+ T cell population as 
propagated by CTLA-4Ig indicates the emergence of bona fide regulatory T cells. Notably, 
these Treg cells, as they are sustained upon a second stimulation even in the absence of 
CTLA-4Ig, appear to represent a stable population. 
The role of Tregs cells in the context of CTLA-4Ig mediated costimulation blockade is 
puzzling. In principle, the homeostasis of Tregs has been proposed to be dependent on CD28 
signalling. Therefore, CTLA-4Ig as it blocks CD28 mediated signal transduction has been 
suspected to negatively interfere with Treg survival [186]. Furthermore, blocking CD80/86 
may also impair counterstimulatory signals to T cells, as provided by CTLA-4 [135]. 
Contrary to this hypothetical view, some reports suggested that CTLA-4Ig leads to an 
augmentation of Tregs [187], possibly by conversion of CD4+25– T cells to CD4+CD25+ T 
cells [188], yet, in an IDO independent fashion [189]. In human studies, CTLA-4Ig was 
shown to fail to enlarge the CD4+CD25+FOXP3 Treg population [190]. In the long term, 
however, CTLA-4Ig did not negatively interfere with Treg survival [192, 198]. Finally, a 
specific role for CD4+ Treg cells for tolerizing the CD8+ population was proposed [167].  
While published reports preclude a definitive conclusion, the findings of this study, i.e. 
CTLA-4Ig propagating Tregs, warrant further testing. Generating Treg populations through 
CTLA-4Ig ex vivo might be beneficial for adoptive transfer strategies after transplantation to 
ameliorate pathogenic alloreactivity in the host-versus-graft as well as in the graft-versus-host 
direction. Such an approach is currently extensively studied in our laboratory.  
In summary, the findings of this study support the view that costimulation blockade by 
CTLA-4Ig achieves potent immunoregulatory activity in an IDO independent fashion. By 
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direct interference with the interaction of APCs and T cells, CTLA-4Ig affects predominantly 
the CD4+ T cell population through two cellular mechanisms, inhibition of proliferation and 
allowing the emergence of a CD4+ cell population harbouring a regulatory phenotype.  
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Figure Legends and supporting information 
 
Figure 1. No induction of IDO and tryptophan metabolism by CTLA-4Ig in C57BL/6 
splenic DCs. (A) Phenotype of splenic DCs after 24h of stimulation with CTLA-4Ig fusion 
proteins (40µg/ml); shaded histograms, isotype control; open histograms, DCs without (grey) 
or with (black) stimulation. One representative of 3 similar experiments is shown. (B) IDO 
mRNA expression as analyzed by RT-PCR. Total RNA of murine Baf3 cells was used as 
negative control and GapdH as internal standard; NTC, non template control. (C) IDO protein 
expression in the same DCs as in (A) analyzed by IB. Human DCs stimulated by LPS/IFN-γ 
as described (19) were used as positive and murine CD3+ T cells were used as negative 
controls. Internal standard, Gapdh. (D) Concentrations of tryptophan (TRP; black bars, left 
scale) and kynurenine (KYN; grey bars, right scale) in cell culture supernatants of the same 
DCs as in (C) as determined by HPLC (n=5). 
 
Figure 2. Induction of IFN-γ release in C57BL/6 splenic DCs by CTLA-4Ig. (A) Cell 
culture supernatants of DCs stimulated as in Fig 1 were examined for IFN-γ release (ELISA, 
left panel) and tryptophan metabolism (as described in Fig 1D, right panel) in parallel. 
Tryptophan (TRP; black bars, left scale) and kynurenine (KYN; grey bars, right scale). (n=3). 
*, p<0,05. 
 
Figure 3. CTLA-4Ig does not induce a DC regulatory phenotype but impairs the 
interaction of stimulator and responder cells in MLRs. (A) C57BL/6 splenic DCs were 
stimulated with CTLA-4Ig fusion proteins for 24h. Thereafter, cells were thoroughly washed 
and co-cultured with Balb/c CD3+ T cells. Proliferative responses were determined by CFSE 
dilution after 6 days and are expressed as per cent CFSE negative cells or as the per cent 
divided cells (see Material and Methods). Results of one experiment, representative of 3 
experiments, are shown. (B) C57BL/6 splenic DCs were stimulated with CTLA-4Ig fusion 
proteins as above. Thereafter, DCs were thoroughly washed and co-cultured with Balb/c 
CD3+ T cells in the presence or absence of CTLA-4Ig (abatacept, 100µg/ml). Proliferative 
responses were examined as in (A). Results of 1 experiment, representative of 3 experiments, 
are shown (P<0.01). (C) Purified Balb/c CD3+ T cell were stimulated with plate bound anti-
CD3/anti-CD28 for 48h in the presence or absence of increasing concentrations of CTLA-4Ig 
fusion proteins. T cell proliferation was assessed by CFSE dilution. Results of 1 experiment, 
representative of 2 experiments, are shown. 
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Figure 4. In an MLR, CTLA-4Ig preferentially affects the CD4+ T cell population. An 
MLR was performed as in Fig 3 in the absence (black bars) or presence (grey bars) of CTLA-
4Ig and the proliferative response (CFSE dilution) was assessed separately for CD4 and CD8 
cells. **, p<0.01; n.s., not significant.  
 
Figure 5. CD4+CD25+ T cells recovered from an MLR performed in the presence of 
CTLA-4Ig harbour a regulatory phenotype. C57BL/6 bone marrow derived DCs 
(BMDCs) were used as stimulators of Balb/c derived CD3+ T cells in the absence or presence 
of CTLA-4Ig (abatacept). At the end of the co-culture, the CD4+CD25+ T cell population was 
examined for the expression of the key cellular markers indicating a regulatory phenotype, 
intracellular FoxP3 and cell surface CD62L. Dotted lines, isotype controls. Balb/c 
CD4+CD25+ cell isolated from lymph nodes and representing naturally occurring regulatory T 
cells (nTregs) were used as positive control. Results of one experiment, representative of 2 
experiments are shown. 
 
Figure 6. Sustained effect of CTLA-4Ig, preferentially in CD4+ cells, in a second MLR. 
(A) BMDCs were used as stimulators of Balb/c derived CD3+ T cells in the absence or 
presence of CTLA-4Ig as in Fig. 5. At the end of the MLR, T cells were recovered and 
stained with CFSE and restimulated with the same DCs but in the absence of CTLA-4Ig. 
Proliferative responses to 2nd stimulation were examined by CFSE dilution, including the 
determination of the per cent divided cells (see inserted numbers) (B) CD4+ T cells of the 
second round MLR were examined for expression of FoxP3 indicating their regulatory 
phenotype, as in Fig 6A.  
 
Supplementary Table 1. Tryptophan (TRP) and kynurenine (KYN) concentrations were 
measured by  HPLC in cell culture supernatants of CD11c+ splenic DCs stimulated for 24h 
with increasing concentrations  (0-100 µg/mL) of CTLA-4Ig (abatacept). 
 
Supplementary Table 2. Tryptophan (TRP) and kynurenine (KYN) concentrations measured 
by  HPLC in cell culture supernatants of CD8α+ splenic DCs stimulated for 24h with 40 
µg/mL CTLA-4Ig (S) or abatacept. 
 
Supplementary Figure 1. The effect of CTLA-4Ig(S) on splenic DCs obtained from DBA/2J 
mice. (A) Splenic DCs were exposed to CTLA-4Ig(S) (40µg/ml) and IDO protein expression 
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was examined by IB as described in Material and Methods. (B) Concentrations of tryptophan 
(TRP; black bars, left scale) and kynurenine (KYN; grey bars, right scale) were examined by 
HPLC in cell culture supernatants of the same DCs as in (A). (C) Cell culture supernatants of 
the same DCs as in (A) were examined for IFN-γ release. 
 
 
 
 
 
88 
 
 
 
89 
 
 
 
 
90 
 
 
 
 
 
91 
 
 
 
 
92 
 
 
 
 
93 
8 Abbreviations 
 
APC    antigen-presenting cell 
BMC    bone marrow cells 
BMDC   bone marrow derived dendritic cells 
BMT    bone marrow transplantation 
CMV    cytomegalovirus 
CNI    calcineurin inhibitor 
CTLA-4   cytotoxic T lymphocyte-associated antigen 4 
CTLA-4Ig   CTLA-4-immunoglobulin 
DC    dendritic cell  
EBV    Epstein-Barr virus 
ELISA    enzyme-linked immunosorbent assay 
FDA    Food and Drug Administration 
GapdH   glyceraldehyde-3-phosphate dehydrogenase 
G-CSF    granulocyte colony-stimulating factor 
GvHD    graft-versus-host disease 
HLA    human leukocyte antigen 
HPLC    high-pressure liquid chromatography 
HSCT     hematopoietic stem cell transplantation 
ICAM-1   intracellular adhesion molecule 1 
iDC    immature dendritic cell 
IDO    indoleamine 2,3 dioxygenase 
IFN    interferon 
IL    interleukin 
iNOS    inducible nitric oxide synthase 
i.p.    intraperitoneal 
LFA-1    lymphocyte function-associated antigen 1 
LPS    lipopolysaccharide 
MACS    magnetic cell sorting 
MHC    major histocompatibility complex 
NAD    nicotinamide-adenine-dinucleotide 
NO    nitric oxide 
NK    natural killer cells 
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PGE2    prostaglandin E2 
p.t.    post transplantation 
RT    room temperature 
RT-PCR   real-time polymerase chain reaction 
TCD    T cell depletion 
TDO    tryptophan 2,3-dioxygenase 
TNF    tumor-necrosis factor 
TNFR    TNF receptor 
TRAFs   tumor necrosis factor receptor-associated factors 
Tregs    regulatory T cells 
TRM    transplant-related morbidity and mortality  
TRP    Tryptophan 
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